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CHAPTER 1 
GENERAL INTRODUCTION 
BACKGROUND AND SIGNIFICANCE 
Cardiac biology 
The cardiovascular system is responsible for transporting the many constituents 
of blood including electrolytes, nutrients, gases, and hormones, to and from all organs in 
the body.  Without the heart to create the appropriate amount of positive pressure, 
organ perfusion would not occur, pH would become out of balance, and cellular 
homeostasis would become severely disrupted.  The general physiology and anatomy 
of the heart are well defined (Fig. 1A,B).  During the cardiac cycle, deoxygenated blood 
enters the right atrium through either the superior or inferior vena cava and is then 
pumped through the tricuspid valve into the right ventricle.  It is then pushed through the 
pulmonic valve into the pulmonary arteries and pulmonary circulation where it is 
reoxygenated in the lungs.    The oxygenated blood re-enters the heart at the left atrium 
by means of the pulmonary veins.  Ventricular diastole then ensues, during which 
ventricular muscle relaxes.  Pressure decreases in the left ventricle, and blood begins to 
enter through the mitral valve which is forced shut after a critical volume is reached.  
Contraction of the left atrium pushes a small amount of blood into the nearly full 
ventricle, increasing its pressure just prior to ventricular systole.  Immediately after, left 
ventricular muscle cells contract and force the oxygenated blood through the aortic 
valve into the aorta and subsequent arterial circulation [1]. 
The left ventricular wall of the heart is responsible for generating the immense 
pressure necessary to circulate blood throughout the body.  It is composed of three 
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tissue layers:  the endocardium, myocardium, and epicardium (Fig. 1B).  The inner-most 
layer, the endocardium, consists of epithelial cells that make contact with blood entering 
the chamber.  The myocardium (medial layer) is the location of the heart muscle cells 
responsible for contraction during systole.  The outer layer is a protective tissue known 
as the epicardium.   The myocardium represents the majority of the left ventricular wall, 
and is composed of layers of cardiomyocytes (heart muscle cells) running in parallel 
(Fig. 1C), connected cytoplasmically by channels known as gap junctions.  Studying the 
 
Figure 1.  Cardiac anatomy and blood flow.  (A) Blood returns to the heart through the 
superior and inferior vena cava, enters the right atrium and is pumped into the right ventricle.  
It then moves through the pulmonary arteries to the lungs, is reoxygenated, and flows into the 
left atrium through the pulmonary vein.  The left ventricle fills, with additional blood being 
forced into the chamber through the mitral valve by the right atrium.  Ventricular contraction 
then pushes the blood into the aorta and throughout the body (arrows, blood flow).  (B) The 
myocardium lies between an inner epithelial layer (endocardium) and an outer connective 
tissue layer (epicardium), and consists of stacks of muscle cells known as cardiomyocytes.  
The myocardium is most dense in the left ventricle, as significant force is needed to drive 
blood through the body.  (C) Rows of cardiomyocytes arrange in parallel to form the 
myocardium.  Figures modified from various sources [2-4]. 
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myocardium at the cellular level is essential to understanding the underlying pathologies 
involved in cardiomyopathies such as cardiac hypertrophy. 
The major histological features of the cardiomyocyte include:  1) numerous rows 
of myofibrils consisting of segments of interdigitating myosin and actin filaments called 
sarcomeres (Fig. 2A); 2) a cytoplasmic membrane structure similar to endoplasmic 
reticulum (ER) known as the sarcoplasmic reticulum (SR); 3) invaginations of the 
sarcolemma (cell membrane) called T-tubules; and 4) a large number of mitochondria 
running next to the myofibrils, to provide adequate ATP for cross-bridging termination 
and to fuel sarco/endoplasmic reticulum Ca2+-ATPases (SERCA2a) [1, 7].  The 
Figure 2.  Myofibrillar structure.  The main constituent of the cardiomyocyte is the myofibril.  
These long cylindrical structures themselves are made of many sarcomeres stacked in series, 
containing multiple types of contractile filaments.  (A) An electron micrograph of the interior of 
a cardiomyocyte highlighting multiple myofibrils running in parallel.  The sarcomere, the area 
between two Z-lines in a myofibril, is the contractile unit in the cell.  (B) Myofibrils are wrapped 
in a network of endoplasmic reticulum-like compartments known as sarcoplasmic reticulum or 
SR.  In the free SR, located between Z-lines, the Ca2+-ATPase SERCA2a pumps Ca2+ into the 
SR network.  The Ca2+ is then released at junctional SR located on Z-lines, through the 
ryanodine receptor after external Ca2+ entering through Ca2+ channels in the cell membrane 
(SL)/T-tubules triggers activation.  Modified from Gottlieb et al. and Sommer et al. [5-6]. 
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sarcomere, the most basic myofibril contractile unit, is bordered on both ends by Z-lines 
(Fig. 2A).  Z-lines are the predominant sites of junctional SR, where SR membrane Ca2+ 
channels known as  ryanodine receptors (RyR2) reside in close proximity to T-tubules 
that provide access to extracellular Ca2+ (Fig. 2B) [6].    
The junctional SR/T-tubule interface is critical for cardiomyocyte contraction, as it 
is the site where calcium-induced calcium release (CICR) is initiated.  Adjacent 
cardiomyocytes 
alter 
membrane 
potentials 
through gap 
junctions, 
leading to 
sarcolemmal 
depolarization, 
which causes 
L-type Ca2+ 
channels in T-
tubules to 
open.  The 
influxing extracellular Ca2+ binds the cytoplasmic side of junctional SR RyR2 channels 
which then open, allowing large quantities of SR Ca2+ to move into the cytoplasm.  the 
Ca2+ subsequently binds troponin T, which releases tropomyosin bonds to actin and 
 
Figure 3.  Calcium-induced calcium release.  Depolarization of the 
heart cell membrane causes the L-type Ca2+ channel (CC) in the T-tubule 
to open, allowing Ca2+ to bind RyR2s located in the junctional SR 
membrane.  The RyR2s then open, and Ca2+ moves into the cytoplasm, 
triggering contraction.  Afterwards, Ca2+ is either pumped out of the cell 
by the Na+/Ca2+ exchanger (NCX) or back into the SR by SERCA2a 
(SERCA), during which time CSQ2/Trd1/Jct complexes promote RyR2 
refractory periods.  Modified from Berridge et al. [8]. 
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triggers contraction.  Ca2+ is then either pumped out of the cell by the Na+/Ca2+ 
exchanger (NCX) or back into the SR by SERCA2a, during which time cardiac 
calsequestrin (CSQ2), triadin-1 (Trd1), and junctin (Jct) theoretically interact to cause a 
RyR2 refractory period (Fig. 3) [8-9]. 
Calsequestrin 
Calsequestrin (CSQ) is a major luminal protein of the junctional SR in muscle, 
where it is thought to play a role in excitation-contraction coupling [10-16].  While both 
skeletal CSQ (CSQ1) and cardiac CSQ (CSQ2) are expressed in skeletal muscle, only 
CSQ2 is present in cardiac muscle, where it is the major Ca2+ binding protein [17].  In 
fact, previous studies have hypothesized that nearly 50% of Ca2+ stored in 
cardiomyocyte SR is bound to CSQ2 [18], which is reasonable given its ability to bind 
large amounts of free Ca2+ (35-40 mol Ca2+/mol CSQ2) [19-20].  CSQ2 shares structural 
properties with classic resident ER proteins such as GRP94 and calreticulin, although 
CSQ2 lacks the C–terminal KDEL retrieval sequence along with any other known 
targeting sequence [17, 21].  These properties allow CSQ2, through an unknown ER 
retention mechanism, to evade secretion and become concentrated in junctional SR 
[10-11, 16, 22].  Recent data supports the hypothesis that CSQ2 retention in ER results 
from its polymerization [23].   
Enrichment of CSQ2 in secretory pathway compartments may be related to its 
tendency to polymerize in the presence of increasing Ca2+.  A model for Ca2+-dependent 
CSQ polymerization has been developed based upon crystal structure, showing linear 
front-to-front and back-to-back CSQ chain formation [24-26].  As luminal SR Ca2+ levels 
increase, CSQ begins front-to-front polymerization due to the lesser charge on its N-
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terminus.  A further increase in Ca2+ causes back-to-back polymerization as more 
cations are needed to shield C-terminal acidic residues.  High luminal Ca2+ levels 
eventually lead to 
the formation of 
CSQ linear 
polymers with 
front-to-front and 
back-to-back 
binding (Fig. 4) 
[26].   
 In addition 
to its proposed 
function as an SR 
Ca2+ buffer, 
CSQ2 is also 
thought to interact 
with cardiac RyR2, the SR integral membrane protein responsible for supplying the 
cytosolic Ca2+ necessary for sarcomeric contraction.  As proposed by Gyorke et al., 
CSQ2 serves as a Ca2+ sensor for the RyR2, promoting a channel refractory period in 
times of low luminal Ca2+ [9].  CSQ2 binds in low Ca2+ to either Trd1 or Jct, both of 
which may be tethered to the luminal side of the RyR2 in junctional SR.  This is thought 
to inhibit RyR2 activity.  As luminal Ca2+ concentrations increase, CSQ2 binds more 
Ca2+ and consequently becomes less tightly bound to Trd1 or Jct allowing stimulation of 
Figure 4.  CSQ2 polymerization.  As luminal SR Ca2+ levels increase, 
CSQ2 begins front-to-front polymerization due to the lesser charge on its 
N-terminus.  Further increases in Ca2+ cause back-to-back 
polymerization as more cations are needed to shield C-terminal acidic 
residues.  High luminal Ca2+ levels lead to formation of CSQ2 linear 
polymers with front-to-front and back-to-back binding.  Modified from 
Park et al. [26]. 
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channel activity.  Eventually Ca2+ levels are high enough to cause CSQ2 dissociation 
from the 
complex, 
allowing the 
RyR2 to reach 
maximal activity 
(Fig. 5). 
CSQ2-
overexpressing 
and CSQ2-null 
transgenic mice 
have been 
developed in an 
attempt to determine CSQ2 protein function in vivo [27-28].  Overexpressing animals, 
with approximately 10-fold increases in cardiomyocyte CSQ2, suffer from severe 
hypertrophy causing heart mass and cell size to increase 2-fold [27].  In knockout mice, 
a hypertrophic phenotype was also reported, along with increased diastolic Ca2+ leak 
with pathology similar to a disease in humans caused by CSQ2 mutation, known as 
catecholaminergic polymorphic ventricular tachycardia (CPVT) [28-29].  Interestingly, 
both overexpression and knockout transgenic models show a significant decrease in 
Trd1 and Jct levels.  Correspondingly, Trd1-null mice show a significant decrease in 
CSQ2 and Jct levels, highlighting a potential interdependence between the three 
proteins.  A summary of the effects of CSQ2 knockout, along with Trd1-null data, can be 
Figure 5.  CSQ2 modulation of RyR2.  CSQ2 is thought to serve as a 
Ca2+ sensor for the RyR2, promoting a refractory period for the channel 
in times of low luminal Ca2+.  CSQ2 binds to either Trd1 or Jct in low 
Ca2+, inhibiting the RyR2.  Increases in luminal Ca2+ concentration cause 
CSQ2 to become less tightly bound to Trd1/Jct allowing stimulation of 
channel activity.  Eventually Ca2+ levels are high enough that CSQ2 
dissociates from the complex and the RyR2 becomes maximally active.  
Modified from Gyorke et al. [9]. 
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Table 1.  Major features of CSQ2-null and Trd1-null mice. 
 
seen in Table 1, modified from Knollmann [30].  Because changes in CSQ2 levels are 
believed to be due to translational regulation [29], it would be beneficial to determine the 
site of CSQ2 synthesis. 
Even without knowledge of the location of CSQ2 translation, it has still been 
possible to obtain data regarding trafficking pathways based upon electrospray 
ionization mass spectrometric analysis of the intact protein [31].  Information regarding 
CSQ2 trafficking results from the ability of mass spectrometry to visualize the entire 
repertoire of CSQ2 structures (glycoforms and phosphoforms) that exist in each 
experimental system [31-32].  An N-linked glycan is added to CSQ2 co-translationally 
(Man9GlcNAc2Glu3) in rough ER, and subsequently undergoes mannose trimming 
upon exposure to various secretory compartments and their respective mannosidases 
(Fig. 6) [31-32].  CSQ2 glycoforms differing in single mannose sugars (∆162 Da) are 
easily discernable in CSQ2 mass spectra, allowing direct visualization of changes that 
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reflect trafficking pathways.  A second important modification of CSQ2 is the 
phosphorylation of its multiple C-terminal serines (Fig. 7, in canine 378, 382, 386Ser) which 
can also be directly visualized (∆81 Da).  Between the possible combinations of 
mannose and phosphorylation states in CSQ2, twelve structural forms can be resolved 
from native heart tissue [31]; yet all will run in a nearly single band with SDS-PAGE 
analysis at approximately 55 kDa [33]. 
 Based upon the distribution of CSQ2 glycan structures (Man9-Man1) in a normal 
mammalian heart, CSQ2 can be separated into two distinct pools [31, 34-35].  The most 
proximal glycoforms (Man9-6) also contain the highest levels of serine phosphorylation 
[31]; in fact all CSQ2 molecules in the heart that have 6 or more mannoses are also fully 
phosphorylated.  This suggests that CSQ2 phosphorylation also occurs at a location 
early in the secretory system.  A second pool is represented by Man1-5 isoforms.  This 
second pool indicates further trafficking of CSQ2, but still represents trafficking that 
 
 
Figure 6.  N-Linked glycosylation.  The standard N-linked glycosylation pathway begins with 
co-translational transfer of the core oligosaccharide.  Following successful folding of proteins in 
the ER, the glycan Man9GlcNAc2 remains intact.  An ER mannosidase I produces the Man8 
form.  Subsequent mannose trimming is generally associated with ER and Golgi 
compartments, but this process has not been examined in heart.  CSQ2 glycan does not 
contain N-terminal GlcNAc.  Modified from Helenius et al. [32].  
10 
 
 
 
Figure 7.  Features of CSQ sequences (sequences from NCBI database).  (Left panel)  
Human cardiac (black) and skeletal muscle CSQ (red) sequences are 60% identical, and 
exhibit conserved glycosylation sites (2nd box from end of the full-length sequence).  The 
cleaved signal sequences are very different, and that difference is conserved among 
species (upper right panel).  Residues highlighted yellow are only examples of near 
identity, for orientation. The cardiac specific tail is seen in all species, and contains CK2-
sensitive serine residues (indicated by black dots under the residues, in addition to yellow 
highlight in left panel, red lettering in lower right panel).  Dotted lines for Rat and Dog C-
termini (lower right panel) designate the fact that cardiac tail is uncertain, since skeletal 
muscle CSQ sequences have not been reported. 
does not involve the Golgi, as Golgi trafficking would lead to addition of more (terminal) 
GlcNAc residues [31-32].  The second CSQ2 pool exhibits a lower level of 
phosphorylation, consistent with data using polymerization-site mutants that shows that 
the state of CSQ2 phosphorylation decreases with anterograde movement through the 
cell [23, 31, 34].  The distribution of glycoforms varies between cardiac and skeletal 
muscle CSQs.   In skeletal muscle CSQ, Man1 (a highly unusual glycoform) represents 
as much as 80% of the total CSQ, while in cardiac muscle, CSQ2 Man1 levels are low 
with Man3,4 (species dependent) dominating [31, 34-35].  In contrast to CSQ2 in heart, 
CSQ2 overexpressed in nonmuscle cells consists of only Man9,8 glycoforms, indicative 
11 
 
 
 
Figure 8.  CSQ2 
masses are altered in 
animal models of heart 
failure (HF).  CSQ2 
protein was purified 
from Control and Heart 
Failure animal heart, 
then directly analyzed 
by mass spectrometry.  
CSQ2 molecules from 
failed hearts were larger 
than CSQ2 from control 
hearts.  Increased mass 
is due to reduced 
mannose trimming (∆ 
mass = 162 Da), 
indicative of a higher 
percentage of CSQ2 in 
early ER (shaded).  A 
second change is a 
decrease in more highly 
processed glycans.  
Mass heterogeneity also 
occurs due to C-terminal 
CSQ2 phosphates (∆ 
mass = 81 Da).  Mass 
peaks and their 
corresponding glycan 
structure and 
phosphorylation state 
are indicated across the 
top of the figure.  
(Canine rapid-pacing 
model) tissue from five 
sham-treated and five 
HF dogs was provided 
by H. Valdivia, Univ. 
Wisconsin.  Animals 
underwent ventricular 
pacing, (HF = 220 beats/min) for 6-8 weeks to induce heart failure.  (Canine micro-embolism 
model) HF was caused by intracoronary microsphere injections leading to ischemic damage, 
tissue from H. Sabbah, Henry Ford Health Systems, Detroit, MI. These data were obtained from 
two Sham treated and two HF dogs, differences are more pronounced than in rapid-pacing.  
(Mouse heart failure as a result of a canine CSQ2 transgene) transgenic mice with an MHC-
promoter driving canine CSQ2 overexpression have been previously characterized.  Adult mice 
have severe heart failure and extreme cardiac hypertrophy.  CSQ2 mass spectra were obtained 
from two cohorts of animals: only 4 transgenic mouse ventricles were needed to obtain sufficient 
CSQ2 for analysis, whereas 40 control mouse hearts were needed to obtain the Control mass 
spectrum.  The glycan structure (GlcNAc2Man8,9) on CSQ2 from these animals is almost 
entirely indicative of ER mannosidase I, suggesting a completely altered trafficking. 
 
Figure 8 
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of its highly efficient ER retention. 
In heart tissue from a canine model of heart failure, CSQ2 glycoforms and 
phosphoforms are highly altered compared to control hearts (Fig. 8).  Mass 
spectrometry of CSQ2 purified from these hearts shows a shift in the degree of 
mannose trimming to a less trimmed pool of molecules.  The underlying cause of this 
apparent retrograde shift is unclear.  Additionally, an approximate doubling of the 
Man8,9 pool occurred.  This may suggest an increase in newly-synthesized CSQ2, still 
in rough ER.  Analysis of CSQ2 mass spectra further indicates a doubling of maximally 
phosphorylated CSQ2, which could also reflect increased ER retention, or inhibition of 
the CSQ2 transport system [35].     
CSQ2 phosphorylation and protein kinase CK2 
 In 1991, Cala and Jones reported a cluster of three phosphorylation sites on 
amino acids 378, 382, 386Ser of canine CSQ2 [36].  These phosphorylation sites reside 
within a cardiac specific tail region that is conserved in all cardiac isoforms in all species 
(Fig. 7).  Cardiac CSQ is phosphorylated on these sites in vivo [31, 36], with isolated 
native CSQ2 showing approximately 50% phosphorylation.  Skeletal muscle CSQ can 
be phosphorylated in vitro on 353Thr but is not phosphorylated in vivo [31, 36].  It was 
subsequently determined that CSQ2 is the major substrate for endogenous 
phosphorylation in heart homogenate (Fig. 9) [34].  Surprisingly, CSQ2 overexpressed 
in nonmuscle cells is phosphorylated to a similarly high extent in vitro and in intact cells, 
suggesting that the mechanism of CSQ2 phosphorylation may be conserved in all 
mammalian cells [31].  While it has remained unclear what endogenous protein kinase 
is responsible for phosphorylating CSQ2 on these sites in vivo, these authors showed 
13 
 
 
 
that the sites were very sensitive in vitro to the protein kinase CK2 (formerly known as 
casein kinase II).  Moreover, the phosphorylation sites are part of a consensus 
sequence for CK2. 
A basic structural requirement for phosphorylation by CK2 is the 
“serine/threonine-X-X-aspartic acid/glutamic acid” motif [37-38].  The fourteen most C-
terminal amino acids of canine CSQ2’s highly acidic tail, SDEESNDDSDDDDE, 
 
Figure 9.  In situ phosphorylation of CSQ2 by an unknown kinase.  Expression of canine 
CSQ2 in primary adult rat and canine heart cells was followed by metabolic labeling with 32Pi.  
Canine (lanes 1–4) or rat (lanes 5–10) heart cell cultures were plated in a laminin-coated 
sixwell dish.  At 2 h post-plating, CSQ2 adenovirus (Ad.CSQ) was added (+), or cells were left 
untreated (−).  In one case, a non-phosphorylatable CSQ2 mutant virus (Ad.nonPP) was 
added (lane 6). After 48 h of treatment, cells in two wells were harvested without labeling for 
immunoblot analysis with anti-CSQ2 antibodies, and visualized with 125I-protein A and 
autoradiography (lanes 1 and 2). Cells in other wells (lanes 3–8) were metabolically labeled 
with 32Pi in label-free medium (DMEM) for 4 h, harvested in 0.1% Triton X-100 containing 
buffer, centrifuged to remove insoluble material, and analyzed by SDS-PAGE and 
autoradiography. Molecular weight standards (in kDa) are indicated. Heart cells from five 
cultures were metabolically labeled for 4h (lane 3–7) whereas one sample was labeled for 8h 
(lane 8). Two culture wells (lanes 9 and 10) were not radiolabeled but were extracted in 0.5 ml 
1% Triton X-100-containing buffer and 50 µl added to a buffer containing 1 mM MgCl2 and 20 
μM [γ -32P] ATP for 10 min at 37°C, before SDS-PAGE and autoradiography.  Arrowheads 
indicate CSQ2.  Modified from Ram et al. [34]. 
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includes three serines that fit the consensus sequence [33, 36].  Although CSQ2 is an 
SR luminal protein, and protein kinase CK2 is known to be a cytosolic or nuclear kinase 
[39], an unknown mechanism must exist that allows for CSQ2 consensus site exposure 
to CK2. 
 Over 500 protein kinases are represented by the human genome [40].  While 
protein kinase CK2 is only one of many, it is one of the more active kinases in 
numerous cell-types [41-42].  CK2 has been reported to phosphorylate hundreds of 
distinct proteins, positively affecting cell proliferation/cell cycle progression and survival 
by means of apoptotic inhibition and other various mechanisms [39, 41, 43-46].  Protein 
kinase CK2 has become the focus of many oncological studies as levels have been 
found to be elevated in human cancers and in transgenic overexpression models [41, 
47-49].   
Although CK2 is traditionally thought of as a holoenzyme, its biochemistry is 
slightly more complex.  CK2 is a tetrameric structure consisting of two catalytic and two 
regulatory subunits [41, 44, 50].  The catalytic subunits, designated CK2α and CK2α′ in 
humans [51], share approximately 90% homology [41], but may possess some level of 
specialization as suppression of one subunit in mouse models does not produce a 
complete compensation by the other [44, 52].  The regulatory subunits, known as CK2β, 
participate in catalytic activity regulation and CK2 substrate selectivity, in addition to 
maintaining tetramer stability during holoenzyme formation [41, 44, 50, 53].  CK2 
regulatory subunits are identical in humans, performing equal roles [54], while they have 
been reported to have separate identities in yeast where they are both essential [55].  
To further complicate protein kinase CK2 research, an overall mechanism has not been 
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deduced that summarizes the regulation of the kinase in cells; as some groups argue 
that CK2 is constitutively active while others claim the influence of extracellular or 
intracellular factors exists [41]. 
In addition to phosphorylating substrate as part of the holoenzyme, the individual 
catalytic subunits CK2α and CK2α′ also have kinase activity independent of the tetramer 
[56-57].  For example, both the holoenzyme and CK2α subunit were shown to 
phosphorylate the cytosolic region of calnexin, a protein that shares many similarities 
with CSQ2 [56].  Interestingly, both catalytic subunits have been shown to localize to the 
cytosolic side of the ER and Golgi apparatus [57].  This data, collectively, suggests that 
CK2 function and regulatory activity is quite complex and will require many future 
studies to explain. 
 Highly specific inhibitors of CK2 have recently been developed and continue to 
be improved due in part to the desirable anti-growth and anti-cancer activities they 
exhibit [58-59].  The three main classes of CK2 inhibitors include:  1) condensed 
polyphenolic compounds; 2) brominated benzimidazole/triazole derivatives; and 3) 
derivatives of indolo quinazolines.  The second class is the most frequently and 
successfully used [60].  The first of these ATP specific binding-site inhibitors of CK2, 
5,6-dichloro-1-(β-ɒ-ribofuranosyl)-benzimidazole (DRB), was designed as a modified 
version of adenosine.  Due to high experimental IC50 values and various off-target 
effects, the popular DRB derivative 4,5,6,7-tetrabromobenzotriazole (TBB, Fig. 10) was 
created by removing the sugar moiety and replacing its chlorines with bulkier bromines.  
TBB was determined to be more potent and selective than DRB, and was also well 
tolerated in live animals for multiple week spans [61].  A slightly modified version of 
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TBB, 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT, Fig. 10) was found 
to have an even higher potency, particularly when tested on cells in culture [62].  
Currently, tetrabromocinnamic acid (TBCA, Fig. 10), the most specific CK2 inhibitor in 
its class, has the lowest Ki (77 nM) [61].  It is thought that TBCA’s acrylic tail increases 
van der Waals interactions, as it allows the brominated benzene ring to move [60]. 
Translation and translocation 
 Translocation of a newly translated protein into the ER lumen can occur after 
translation is completed or concurrently with translation.  The latter is referred to as co-
translational translocation.  During this process, signal sequences within a nascent 
polypeptide are recognized by universally conserved factors in the cytosol and 
membrane in order to mediate their selective targeting, translocation, and/or membrane 
insertion (Fig. 11A) [64].  These events proceed when the hydrophobic core of the 
signal sequence from the newly-synthesized protein protrudes from the ribosome and 
becomes bound by the signal recognition particle (SRP), forming the SRP-bound 
ribosome nascent chain complex (RNC).  Interaction with the SRP receptor (SRP-R) 
Figure 10.  Development of CK2 inhibitors.  Inhibitors of protein kinase CK2 were initially 
designed to mimic ATP structure.  The specific inhibitor TBB was created to better fit the 
unique ATP binding site of CK2.  TBB was modified to produce DMAT, increasing the 
molecules potency.  TBCA represents the most potent and specific of this class of ATP-
competitive binding site inhibitors of CK2.  Modified from Duncan et al. and Sarno et al. [61, 
63]. 
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allows the RNC to be targeted to the ER membrane, where it is then transferred to an 
adjacent translocon followed by subsequent dissociation of the receptor-bound SRP 
complex via GTP consumption.  The ribosome binds to the Sec61 complex (Fig. 11B), 
placing the signal sequence in close proximity to the translocating chain-associating 
membrane protein (TRAM) and Sec61.  If the signal sequence is recognized sufficiently 
by the Sec61 complex, nascent chain insertion into the hydrophilic pore occurs with a 
concurrent tightening of the bond between the ribosome and translocon.  After further 
elongation of the nascent chain, with its simultaneous translocation into the ER, it can 
interact with the oligosacharyl transferase complex (OST) and signal peptidase complex 
Figure 11.  Co-translational 
translocation.  (A) As translation 
begins, the nascent chain signal 
sequence protrudes from the 
ribosome and is bound by SRP.  
The complex is then trafficked to 
an ER translocation site where 
SRP is bound by the SRP 
receptor and the ribosome binds 
to the Sec61 pore complex.  SRP 
hydrolyzes GTP and releases 
from the signal sequence, 
ribosome, and eventually the 
SRP receptor, leaving the signal 
sequence to interact with Sec61 
and TRAM complexes.  The 
nascent chain is then further 
synthesized while being 
translocated into the ER lumen, 
possibly receiving a glycan from 
the OST complex and/or having 
its signal sequence removed by 
the SPC.  (B) A to scale 
depiction of the rough ER 
translocon showing theoretical 
spacial approximations of various 
complexes according to their 
interactions with one another  
(SP, signal peptidase).   Modified 
from Johnson et al. and Kalies et 
al. [65-66]. 
18 
 
 
 
causing glycosylation and signal sequence cleaving, respectively, given the nascent 
chain sequence permits [64, 66]. 
In part due to their extreme sequence diversity, it has been proposed that signal 
sequence interaction with Sec61 is influenced by the signal’s intrinsic ability to attract 
specific translocaton altering substrates, termed accessory factors [64].  These 
modulators (accessory factors) can include membrane proteins, cytosolic proteins and 
luminal proteins, i.e. chaperones.  These substrates allow for proper positioning of the 
nascent chain in preparation for subsequent translocation.  
A universal property of signal sequences is their overall hydrophobic nature, 
highlighted by the presence of an uninterrupted stretch of no less than six 
nonhydrophilic residues [64].  When a comparison of signals is made between cardiac 
and skeletal calsequestrin isoforms from various species, it can be noted that the 
hydrophobic core is much more significant in skeletal muscle (Fig. 7).  This difference in 
hydrophobicity can affect interactions with the translocon apparatus [64], and may 
contribute to the ability of cardiac calsequestrin to become phosphorylated during 
translocation. 
Significance 
CSQ2 is capable of binding large amounts of Ca2+ within the secretory system in 
cardiomyocytes.  It is also thought to regulate RyR2 activity in junctional SR.  Previously 
published data shows that CSQ2 trafficking is altered in heart failure.  A change in 
CSQ2 localization within the cell could result in a significant Ca2+ microdomain shift, 
capable of altering cellular biochemistry.  In order to investigate this pathological 
phenomenon properly, the site of CSQ2 synthesis, and the protein’s subsequent 
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trafficking pathway must first be elucidated.  Additionally, possible effectors of CSQ2 
trafficking, such as polymerization and phosphorylation, must be explored. 
SPECIFIC AIMS OF DISSERTATION 
Specific aim 1 
 Determine the pathway(s) of CSQ2 trafficking in the adult cardiomyocyte.  
Hypothesis: CSQ-DsRed fusion protein exhibits retention in rough ER and reflects 
normal CSQ2 trafficking pathways, involving polymerization. 
Specific aim 2 
 Confirm the identity of CSQ2 kinase and determine the effects of CSQ2 
phosphorylation.  Hypothesis: CSQ2 is phosphorylated by protein kinase CK2, which 
may affect its ER-retention. 
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CHAPTER 2 
EFFECTS OF A DYNAMIC MONOMER/POLYMER EQUILIBRIUM ON CARDIAC 
CALSEQUESTRIN TRAFFICKING 
ABSTRACT 
 CSQ2 is synthesized in rough ER but concentrates within the junctional SR  
lumen where it becomes part of the Ca2+-release protein complex. To investigate CSQ2 
trafficking through biosynthetic/secretory compartments of adult cardiomyocytes, CSQ-
DsRed was overexpressed in cultured cells and examined using confocal fluorescence 
microscopy.  By 48 h of adenovirus treatment, CSQ-DsRed fluorescence had 
specifically accumulated in the nuclear envelope, where it co-localized with markers of 
rough ER.  From rough ER, CSQ-DsRed appeared to traffic directly to junctional SR 
along a transverse (Z-line) pathway along which sec 23-positive (ER-exit) sites were 
enriched.  In contrast to DsRed direct fluorescence that presumably reflected DsRed 
tetramer formation, both anti-DsRed and anti-CSQ2 immunofluorescence did not detect 
the perinuclear CSQ-DsRed protein, but labeled only junctional SR puncta.  These 
putative CSQ-DsRed monomers, but not the fluorescent tetramers, were observed to 
traffic anterogradely over the course of a 48 h overexpression from rough ER towards 
the cell periphery.  We propose a new model of CSQ2 and junctional SR protein 
trafficking in the adult cardiomyocyte, wherein CSQ2 traffics from its juxtanuclear site of 
biosynthesis, along contiguous ER/SR lumens in cardiomyocytes as a mobile monomer, 
but is retained in junctional SR as a polymer. 
INTRODUCTION 
 CSQ2 is a major protein of the junctional SR lumen in heart [11, 17, 67].  Its role 
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in cardiomyocyte function is not yet clear, and may be multi-faceted [30, 68-69].  
Overexpression studies in cultured myocytes support a role as a buffer of luminal Ca2+ 
[13], whereas data from CSQ2 knockout mice suggest a role in regulation of release of 
Ca2+ through the RyR2 Ca2+ channel [28].  Interestingly, transgenic CSQ2 
overexpressing [27] and knockout mouse models [28], also exhibit unexplained changes 
in the levels of other junctional SR proteins, such as Trd1, Jct, and RyR2.  These larger 
changes in junctional SR protein levels highlight our poor understanding of the 
biosynthetic/secretory system of the adult cardiomyocyte, of which ER, free SR, and 
junctional SR are all a part [70].  
Polymerization of CSQ is now thought to play a critical role in its biology, and is 
predicted to occur in response to high luminal ER/SR Ca2+ [26, 68-69].  Although difficult 
to study in myocytes, studies of CSQ2 overexpression in nonmuscle cells have clearly 
shown how polymerization can also determine CSQ2 localization [23, 71-72].  In 
mammalian nonmuscle cells, each CSQ isoform (cardiac or skeletal muscle) undergoes 
polymerization that leads to its concentration in a specific cellular compartment.  
Cardiac CSQ concentrates exclusively in the ER of all nonmuscle cells, whereas 
skeletal muscle CSQ concentrates in the ER-Golgi intermediate compartment (ERGIC).  
The distinct sites of localization for the two CSQ isoforms were the result of their 
specific polymerization properties [71].  In this same way, polymerization of cardiac 
CSQ in adult cardiomyocytes might occur specifically in junctional SR puncta, brought 
about by the ionic milieu of junctional SR lumens.   
Another biochemical property of cardiac CSQ that is likely to play a role in its 
biology is phosphorylation on two or more serines in the cardiac-specific tail [31, 34, 36].  
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These C-terminal protein kinase CK2 consensus sequences are present in all cardiac 
isoforms of CSQ and are exquisitely sensitive to CK2 in vitro.  This modification is 
believed to occur at the rough ER of the cardiomyocyte where it may affect CSQ2 
translocation or CSQ2 trafficking from rough ER to junctional SR [34].  CSQ2 glycans 
show trimming by cellular mannosidases with no other modification.  Because N-acetyl 
glucosamine (GlcNAc) would be found on CSQ2 glycans were CSQ2 to traffic to early 
Golgi compartments [23, 73], it becomes likely that CSQ2 remains inside classical 
mammalian ER.   
In a canine tachycardia-induced model of hypertrophy that leads to heart failure, 
CSQ2 glycosylation and phosphorylation are very significantly altered [35].  CSQ2 
glycan structures in the hypertrophic heart show a two-fold increase in ER-localized 
CSQ2 and a roughly two-fold increase in levels of phosphorylated CSQ2 in the ER [35].  
The cellular processes underlying these changes have remained uncertain due to the 
lack of understanding of CSQ2 biosynthesis and trafficking in the adult cardiomyocyte. 
In the present study, we used confocal imaging techniques to investigate the 
direct fluorescence of CSQ-DsRed along with a complementary indirect 
immunofluorescence, to outline ER and SR regions in adult cardiomyocytes that parallel 
putative CSQ2 compartmentation based upon on its biochemistry.  
MATERIALS AND METHODS 
Heart cell preparation and culture  
This investigation conforms with the Guide for the Care and Use of Laboratory 
Animals published by the US National Institutes of Health (NIH Publication No. 85-23, 
revised 1996).  Animal research was approved by the Wayne State University Animal 
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Investigation Committee (protocol # A 06-07-07).  Excised Sprague-Dawley (Rattus 
norvegicus) rat hearts were perfused using a Langendorff apparatus for 5 min before 
enzymatic dissociation using a 40 ml solution consisting of Liberase Blendzyme (Roche) 
types 1 and 2 (3 mg/6 mg) in Hank’s buffer containing 5 mM pyruvic acid, 1.2 mM 
MgSO4, 5 mM creatine, 11 mM Glucose, 5 mM taurine, 5 mM carnitine and 0.1 mM 
CaCl2 (20 min).  Cells were titurated for 10 min at 37ºC, filtered, pelleted at 300 x gmax, 
then washed in phosphate buffered saline (PBS) containing gradually increasing CaCl2 
during 3 consecutive washes, to a concentration of 500 µM CaCl2, after which cells 
were resuspended in Medium 199 containing 2% bovine serum albumin, 2 mM 
carnitine, 5 mM creatine, 5 mM taurine, 2 mM L-glutamine, 2 mM Glutamax-1 
(Invitrogen), ITS mixture (Sigma I3146), 100 units/ml penicillin G, 0.1 mg/ml 
streptomycin and plated on laminin-coated dishes at 37ºC with 5% CO2.  
CSQ plasmid and adenoviral constructs 
CSQ constructs were generated from wild type canine cardiac CSQ cDNA λgt10 
clone IC3A [33].  Adenoviral CSQ-DsRed (Ad.CSQ-DsRed) was created using the 
AdEasy XL Adenoviral Vector System (Stratagene) after canine cardiac CSQ cDNA had 
been cloned into pDsRed2-N1 vector as previously described [71].  Adenoviral CSQ-
hemagglutinin (Ad.CSQ-HA) was previously described [23].   
Adenoviral-mediated overexpression 
 Recombinant adenoviral treatment was carried out in cultured adult rat primary 
cardiomyocytes as previously described [31].  Adenoviruses were added directly to 
dishes 2 h post-plating at a multiplicity of infection (MOI) of 100.  Virus treatments were 
routinely carried out for 48 h before harvesting for biochemical analysis or fixing for 
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microscopy as described below. Individual dishes and coverslips were incubated for 
shorter or longer times as indicated.  
Antibodies 
 Monoclonal antibodies specific to cardiac CSQ and RyR2 were the generous gift 
of Dr. Larry Jones, Indiana University School of Medicine.  Rabbit polyclonal antibodies 
raised to canine CSQ2 were purchased from Abcam (ab3516).  Rabbit polyclonal anti-
HA antibody was purchased from Sigma-Aldrich.   Rabbit polyclonal anti-sec23 antibody 
was obtained from Affinity BioReagents.  Rabbit polyclonal anti-DsRed antibody was 
purchased from Clontech.  Rabbit polyclonal antibodies specific to translocon-
associated protein complex (TRAP) and translocating chain-associated membrane 
protein (TRAM) were the generous gift of Dr. Ramanujan Hegde, National Institute of 
Child Health and Human Development, NIH.  Alexa Fluor 488-conjugated goat anti-
rabbit IgG, Alexa Fluor 488-conjugated goat anti-mouse IgG and Alexa Fluor 568-
conjugated goat anti-mouse IgG secondary antibodies were purchased from Invitrogen.  
Immunoblotting 
SDS-PAGE was carried out according to Laemmli [74] on 7.5% acrylamide gels, 
transferred to nitrocellulose membranes (0.45 µm, Bio-Rad Laboratories) and stained 
with Amido black (Sigma).  Immunoblotting was carried out as previously described [42] 
using HRP-coupled secondary antibodies.  Horseradish peroxidase (HRP)-conjugated 
goat anti-rabbit IgG and goat anti-mouse IgG secondary antibodies were obtained from 
Jackson ImmunoResearch Laboratories.  A SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific) electrochemiluminescence (ECL) kit was used according 
to the manufacturer’s protocol to detect immune complexes, which were then visualized 
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by autoradiography using Amersham Hyperfilm ECL film (GE Healthcare).  Protein 
concentrations were determined according to Lowry [75]. 
Fluorescence microscopy 
Cells were fixed on coverslips with 4% paraformaldehyde in PBS for 10 min and 
then permeabilized for 5 min in 0.2% Triton X-100.  Coverslips were blocked in PBS 
with 0.2% Tween-20 (PBS/Tween) and 2% goat serum at room temperature for 1 hour.  
Cells were then incubated in PBS/Tween with primary antibody (1:200) for 90 min at 
ambient temperatures, followed by washing in PBS/Tween, and incubation with goat 
anti-rabbit IgG or goat anti-mouse IgG antibodies conjugated to Alexa Fluor dyes (1:500 
dilution in PBS/Tween for 60 min).  Cells were counterstained with 100 μM 4′-6-
diamidino-2-phenylindole (DAPI) for 2 min, rinsed, and mounted to microscope slides 
with ProLong Antifade Mounting Kit (Molecular Probes).  Confocal microscopy was 
performed at the Microscopy and Imaging Resources Laboratory at Wayne State 
University, School of Medicine.  Imaging was performed using a C-Apochromat 63x/1.2 
WKorr water objective on either a Zeiss LSM 510 laser scanning microscope or an 
Axioplan2 Imaging fluorescent microscope with Apotome imaging, or using a 63x/1.4 oil 
objective on a Leica TCS SP5 laser scanning microscope.  Laser scanning images were 
acquired on a 1024 x 1024 pixel canvas with 8-line averaging.  Apotome images were 
obtained with a Zeiss Axiocam MRm B/W CCD camera.  Confocal images were 
processed and optimized offline for publication using Photoshop (Adobe Systems Inc.).  
Z-stack images created by the Leica TCS SP5 were compiled and optimized in ImageJ 
(Wayne Rasband, National Institutes of Health). The ImageJ 3D Viewer plugin was 
used to create three-dimensional z-stack images. 
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Figure 12.  Perinuclear 
localization of CSQ-DsRed
in cultured adult rat
cardiomyocytes.  (A)
Cultured primary adult rat
cardiomyocytes plated on
glass coverslips were treated
with Ad.CSQ-DsRed for 48 h,
and DsRed fluorescence was
analyzed by confocal
fluorescence microscopy
after fixation.  (B) Cells 
treated with Ad.CSQ-DsRed
(red) were stained with anti-
RyR2 antibodies (green).
Enlarged area (white box in 
panel B) shows RyR2
immunostaining (C) or CSQ-
DsRed fluorescence (D).  (E)
a merge of C and D, shows
imperfect co-localization of
CSQ-DsRed and RyR2.  (F)
Cells co-infected with
Ad.CSQ-DsRed (red) and
Ad.CSQ-HA (green) were
stained with anti-HA 
antibodies. Bars, 20 µm
(panels A,B,F) or 2 µm
(panels C,D,E).  Imaging,
Apotome (panels A,F), Leica,
(panels B-E). 
RESULTS 
CSQ-DsRed is localized to perinuclear regions of the cardiomyocyte 
 Following its overexpression in cultured adult rat cardiomyocytes, the fluorescent 
fusion protein CSQ-DsRed produced a unique pattern of subcellular localization in 
which both myonuclei were surrounded by intense red fluorescence (Fig. 12).  Red 
fluorescence could be visualized in most cells after 32 h of virus treatment, consistent 
with levels of overexpression observed by immunoblotting (Fig. 13).  CSQ-DsRed 
accumulated in cardiomyocytes to levels that were comparable to endogenous levels of 
CSQ2 after 48 h, by which time CSQ-DsRed prominently surrounded both nuclei 
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Figure 13.  Immunoreactivity and specificity of anti-CSQ2, anti-DsRed, and anti-
sec23 antibodies examined by immunoblotting as a function of CSQ-DsRed 
overexpression.  Following addition of Ad.CSQ-DsRed, cardiomyocytes were cultured 
for indicated times (24-44 h).  Cells prior to adenovirus treatment are shown as t = 0.  
Cells were harvested in SDS-containing buffer and whole cell homogenates (equal 
volumes from each cardiomyocyte dish, roughly 80 µg) were analyzed by SDS-PAGE 
and immunoblotting.  The nitrocellulose membrane was stained with amido black (Protein 
stain), then probed with either anti-CSQ2 (t = 0, 24-40 h), anti-DsRed (t = 44 h), or anti-
sec23 antibodies.  Mobilities of molecular weight standards in kDa, left margin. 
producing a pattern that was qualitatively similar for hundreds of cells examined.  We 
observed a very similar pattern of CSQ-DsRed localization in dishes of live (unfixed) 
cultured cardiomyocytes (data not shown).  In addition to a very high level of red 
fluorescence that appeared in close apposition to the nucleus, CSQ-DsRed could be 
seen, albeit with much lower intensity, in perinuclear puncta.  At these sites, the pattern 
of CSQ-DsRed fluorescence was similar (Fig. 12C,D) but not identical (Fig. 12E) to 
RyR2-positive immunofluorescence.  Peripheral CSQ-DsRed puncta became more 
apparent with increasing time of virus treatment in culture, or when images were 
brightened offline.  In contrast to the peculiar CSQ-DsRed localization, the CSQ2-fusion 
protein CSQ-HA was uniformly present in puncta throughout the cell, and never 
exhibited the perinuclear enrichment observed using CSQ-DsRed (Fig. 12F).  This 
suggested that the concentration of perinuclear CSQ-DsRed had resulted from the 
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Figure 14.  Labeling of the cardiomyocyte rough ER using classic rough ER markers.
Cardiomyocytes were treated with CSQ-DsRed adenovirus for 48 h (red, A-C,E). Anti-
TRAPα images (green) were acquired from three optical planes starting from atop the
nucleus (A), and 2.2 µm (B) or 4.4 µm (C) below (bar, 20 µm).  Panels 1-3 (TRAPα, CSQ-
DsRed, merge, respectively) are enlargements of the leftmost nucleus of each cell shown in
A-C (bar, 2 µm).  Transverse trafficking of CSQ-DsRed can be seen in the optical plane that
dissects the nuclear midline (B2, asterisk) but appears as distinct cisternae in an adjacent
optical slice (C2, double asterisk).  Anti-TRAM immunofluorescence (green) was imaged in
cardiomyocytes not treated with Ad.CSQ-DsRed, but immunostained with ant-RyR (red): D1,
rightmost nucleus in panel D.  Bar, 2 µm.  (E) anti-ribosomal S6 protein immunofluorescence
(green) was imaged in cells overexpressing CSQ-DsRed (red).  Bar, 2 µm.  Imaging, Leica
(panels A-D), Zeiss LSM (panel E).  (F) immunoblot analysis of rat and dog heart
homogenates (H, 100 µg) and microsomal vesicles (MV, 50 µg) using anti-TRAPα
antibodies.  Mobilities of molecular weight standards in kDa, left margin. 
characteristic tetramerization of the DsRed portion of the fusion protein [76-77]. 
CSQ-DsRed around the nucleus co-localizes with rough ER markers 
We hypothesized that the localization of CSQ-DsRed around the nucleus 
represented its site of biosynthesis, that is, cardiac rough ER.  To determine whether 
markers of rough ER supported the juxtanuclear localization of cardiac rough ER, we 
immunostained cultured cardiomyocytes with antibodies against components of the 
protein biosynthesis and translocation machinery.  TRAP is a major protein component 
of the translocon in mammalian cells, where it is involved in nascent protein 
translocation across the rough ER membrane [78].  Indirect immunofluorescence of the 
subunit TRAPα in cultured cardiomyocytes expressing CSQ-DsRed strongly labeled the 
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myocyte perinuclear region, co-localizing with CSQ-DsRed fluorescence (Fig. 14A-C).  
Levels of anti-TRAPα immunofluorescence were highest in cisternae closely apposed to 
the nucleus, whereas CSQ-DsRed could be seen in selected optical slices to extending 
beyond to successive cisternae (panel C2, double asterisk).  A single optical slice was 
sometimes able to capture transverse trafficking as a continuous CSQ-DsRed 
fluorescence between the perinuclear region and an adjacent cisterna (panel B2, 
asterisk).  The abundance of TRAPα in cardiomyocyte membranes was also evident by 
immunoblotting, where it appeared as a single immunoreactive protein band of roughly 
34 kDa [79] enriched in microsomes prepared from either rat or canine heart tissue (Fig. 
14F).  Further support for the idea that the perinuclear region could be a major site of 
protein synthesis in cardiomyocytes came from localization of the translocon accessory 
protein TRAM [80] and the ribosomal S6 protein (Fig. 14D,E respectively) to areas 
surrounding the myonucleus. 
Transport of proteins from the rough ER in mammalian cells is associated with 
the formation of ER exit sites that become COPII transport vesicles [81-83].  Because 
fluorescence microscopy of CSQ-DsRed suggested a relatively direct transport step 
between its apparent site of biosynthesis (perinuclear rough ER) and adjacent junctional 
SR puncta, we asked whether ER exit site location might also reflect such transport in 
cardiomyocytes.  Sec23 is a well-characterized marker of ER exit sites and COPII 
vesicles in mammalian cells [84].  In untreated cardiomyocytes, sec23 produced a 
pattern of immunostaining along Z-lines that was interspersed with RyR2-positive 
staining (Fig. 15A and inset).  This suggested that sec23 might be bound to membrane 
surfaces of cisternae along Z-lines.  When sec23 localization was analyzed in cells 
30 
 
 
 
Figure 15.  Sec23 subcellular localization in cultured rat 
cardiomyocytes.  (A) cultured rat cardiomyocytes were 
immunostained using anti-sec23 antibodies (green), and anti-
RyR2 antibodies (red, shown only in inset).  Inset, sec23, RyR2, 
and merge (top to bottom) of representative Z-lines.  (B) cultured 
cardiomyocytes were treated with Ad.CSQ-DsRed (red) for 48 h. 
Red (CSQ-DsRed) and green (sec23 immunofluorescence) 
channels are shown superimposed.  Bar, 20 µm.  Images, Leica 
TCS SP5. 
overexpressing CSQ-DsRed, sec23 appeared to be bound to the perinuclear membrane 
compartment enriched in CSQ-DsRed (Fig.15B).  Because CSQ-DsRed is expected to 
be an intralumenal ER protein whereas sec23 is a cytosolic protein, such interactions 
could not theoretically be direct, and would presumably require a transmembrane signal 
resulting from enhanced levels of lumenal CSQ-DsRed.  The reason for this 
unexplained translocation of sec23 was not further investigated, but could reflect the 
inefficient ER exit of CSQ-DsRed.  Sec23 levels measured by immunoblotting and 
densitometry exhibited 
a roughly 25% 
decrease in cells 
treated with Ad.CSQ-
DsRed, but showed no 
further changes with 
time of adenoviral 
treatment (Fig. 13, 
rightmost panel).    
Direct CSQ-DsRed 
fluorescence is 
distinct from indirect 
CSQ-DsRed 
immunofluorescence 
 Although CSQ-DsRed was readily detected on immunoblots using either anti-
DsRed or anti-CSQ2 antibodies (Fig. 13), we were surprised to find that after 48 h of 
31 
 
 
 
Figure 16.  CSQ-DsRed fluorescence
versus anti-DsRed immunofluorescence.
Cardiomyocytes were treated with CSQ-
DsRed adenovirus for 48 h, then fixed and
stained with anti-DsRed antibodies.
Confocal fluorescent images were obtained
(z-stack consisting of 38 x 0.5 µm optical
slices) on the Leica TCS SP5; selected
slices are shown (z = 2.5, 3.5, 5.0, 8.0, 9.5
µm for panels A, B, C, D and E,
respectively).  CSQ-DsRed fluorescence
(red) and indirect anti-DsRed (green)
fluorescence are shown together in all
panels (bar, 10 µm).  The entire Z-stack was
assembled into a three-dimensional image
using the ImageJ 3D Viewer plugin in
conjunction with ImageJ software, and
cropped at the first nucleus in order to
highlight the radial distribution and
separation of CSQ-DsRed tetramers (red)
and monomers (green) (panel F).  An
enlargement of the boxed area in E (panel
G), representing a peripheral slice of the
cardiomyocyte, shows the presence of
CSQ-DsRed tetramer largely in
compartments distinct from the monomer
(bar, 1 µm).  The boxed area in G was also
enlarged (panel H) to show non-
colocalization occurring even at the
sarcomeric level, where it appears that
CSQ-DsRed tetramers redirect into free-SR
rete.  Bar, 0.5 µm. 
DsRed overexpression, neither anti-DsRed nor anti-CSQ2 antibodies were able to 
detect CSQ-DsRed in the perinuclear compartments of fixed cardiomyocytes (Figs. 16-
18).  Instead, anti-DsRed and anti-CSQ2 antibodies prominently labeled the cell 
periphery.  This result was seen with three separate antibodies to the CSQ-DsRed 
fusion protein (Fig. 17C, 17D, and 18F).     
 As discussed below, a likely explanation for the loss of immunoreactivity was that 
interaction of antibodies was lost due to the (predicted) tetrameric structure of DsRed 
[76-77].   This did lead, however, to a labeling of two separate pools of overexpressed 
CSQ-DsRed having alternate subcellular distributions.  As supported in experiments 
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below, and discussed in later sections, we interpreted the red and green labeling as 
tetrameric CSQ-DsRed and an immunoreactive CSQ-DsRed monomer, respectively.  
The perinuclear versus peripheral (tetrameric versus monomeric) staining patterns were 
seen in sequential optical slices (z-stack), validating a 3-dimensional distribution of the 
direct DsRed fluorescence near the nucleus (Fig. 16A-E).  Indeed, the radial nature of 
the direct DsRed fluorescence was apparent in virtual transverse slices of the 
reconstructed z-stack along its longitudinal length (Fig. 16F).  Closer examination of an 
optical slice (panel G) near the cell periphery (panel E) where green 
immunofluorescence (CSQ-DsRed monomers) dominates direct red fluorescence 
(CSQ-DsRed tetramer), revealed an imperfect co-localization of the two forms.  Higher 
magnification of the two fluorescent signals confirmed minor differences in distribution at 
the level of individual sarcomeric SR structure (panel H).  Even where indirect and direct 
CSQ-DsRed fluorescence signals occurred together, a distinct distribution was revealed 
for each, perhaps suggesting that CSQ-DsRed tetramers and monomers traffic 
differently. 
 To further analyze the relationship between CSQ-DsRed fluorescence and its 
immunoreactive forms, we examined a time course of overexpression by confocal 
fluorescence microscopy.  Whereas CSQ-DsRed fluorescence did not develop until 
about 32 h of adenovirus treatment, anti-DsRed and anti-CSQ immunofluorescence 
were both detected after only 16-20 h, appearing around nuclei (Figs. 17,18).  Time-
dependent changes in CSQ-DsRed fluorescence and immunofluorescence were 
consistent with its translation and accumulation in perinuclear rough ER after 16 h, 
followed by its increasing concentration in the same region as a red fluorescent 
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Figure 17.  Time-dependent 
changes in anti-CSQ2
immunofluorescence during
CSQ-DsRed overexpression.
Cardiomyocytes were left
untreated (A), or treated with
CSQ-DsRed adenovirus for 20 h
(B) or 48 h (C,D) before fixation
and pemeabilization.  Fixed cells
were immunostained with
monoclonal anti-CSQ2 
antibodies (green) (A-C) or rabbit 
polyclonal anti-CSQ2 antibodies
(D), and analyzed for red DsRed
fluorescence and green
immunofluorescence using laser
confocal microscopy (Leica TCS
SP5).  The inset in panel B
shows a portion of the cell which
is brightened offline so that
fluorescence of endogenous 
native rat CSQ2 is similar in
panels A and B.  Bar, 20 µm. 
polymer.  Once juxtanuclear polymerization occurred, CSQ-DsRed, already in junctional 
SR, continued its anterograde movement towards the cell periphery where it appeared 
to concentrate by 48 h as (green) monomer.  The fact that this movement of 
immunofluorescent CSQ-DsRed could be visualized suggested that additional CSQ-
DsRed was not being generated along the rough ER-junctional SR pathway, perhaps 
because all CSQ-DsRed monomer was scavenged within the perinuclear region by the 
polymer.     
 The fluorescence staining pattern of native rat CSQ2 could be seen in untreated 
(control) heart cells exhibiting a steady-state distribution characteristic of junctional SR 
puncta (Fig. 17A).  Visualization of native rat CSQ2, however, required fluorescence 
acquisition times that produced overexposures of CSQ-DsRed immunofluorescence 
(Fig. 17B, inset), so was not visible with the exposure times used in subsequent figures.  
In contrast to the relatively unchanging pattern of native CSQ2 over a 48 h time course 
34 
 
 
 
Figure 18.  Time-dependent changes in CSQ-DsRed fluorescence 
and anti-DsRed immunofluorescence. Cardiomyocytes were left 
untreated (A), or treated with CSQ-DsRed adenovirus for 16 h (B), 20 h 
(C), 24 h (D), 36 h (E), or 48 h (F) before fixation and permeabilization.  
Fixed cells were immunostained with anti-DsRed antibodies (green), and 
analyzed for red DsRed direct fluorescence and green indirect 
immunofluorescence using laser confocal microscopy (Leica TCS SP5).  
Bar, 10 µm. Magnifications among panels are similar but may vary 
slightly to better illustrate structural differences. 
(not shown), overexpressed CSQ-DsRed immunofluorescence exhibited a time-
dependent 
trafficking.    
 To 
summarize, our 
data suggest 
that the 
tetrameric form 
of CSQ-DsRed, 
while necessary 
to produce the 
intense red 
fluorescence, 
was relatively 
incapable of interaction with antibody molecules.  Meanwhile, antibodies to either half of 
the fusion protein detected CSQ-DsRed monomers which exhibit highly reduced, if any, 
intrinsic (direct) fluorescence.  The data indicate that once CSQ-DsRed tetramerizes 
within rough ER, its anterograde trafficking is very substantially restricted, whereas 
molecules that do not incorporate into the polymer within the nuclear envelope, populate 
increasingly peripheral junctional SR sites.  Based upon these new studies on CSQ2 
trafficking from rough ER to junctional SR compartments, and our recent work on 
polymer-dependent trafficking of CSQ2 in nonmuscle cells [23, 71], we propose a new 
model of CSQ2 trafficking and junctional SR biology in the adult cardiomyocyte.   
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DISCUSSION 
In nonmuscle cells, we previously concluded that CSQ2 is retained within specific 
secretory compartments by virtue of its polymerization [23, 71].  CSQ2 polymers 
accumulate in discrete secretory compartments presumably because soluble protein 
cargo integration into COPII vesicles is very inefficient for large polymers [71, 85-86].  In 
nonmuscle cells, cardiac CSQ polymers form in an early ER compartment comprised of 
polygonal cisternae throughout the cell, but are absent from the ERGIC [23].  This 
subcellular localization for CSQ2 is also reflected in the structure of its N-linked glycan, 
which is always found in an unprocessed form (GlcNAc2Man9,8).  
Skeletal muscle CSQ localizes not to ER, but exclusively to the intermediate 
compartment (ERGIC) of nonmuscle cells [71].  The remarkable difference between 
localization of these two CSQ isoforms within the same cell type underscores the 
relationship between polymerization and localization in mammalian cells.  Thus, not only 
can CSQ polymerize in vivo, but differences in milieu that exist within lumens of two 
consecutive and juxtaposed subcompartments (ER and ERGIC) are sufficient to 
completely discriminate and segregate these two forms of CSQ.  Differences in the 
glycan structures on a conserved Asn316 in the two proteins are also consistent with the 
differential localization [71].  
Tetramerization of DsRed is a documented aspect of its structure [76-77]; in fact, 
DsRed fluorescence is thought to require its tetramerization, although a monomeric 
form exhibiting greatly reduced fluorescence has been generated through numerous 
point mutations [77].  Thus, when fused with CSQ2, tetramerization of DsRed led to its 
effective retention, probably because of inefficient anterograde trafficking, similar to that 
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reported for cardiac CSQ polymers in nonmuscle cells [23, 71].  It is also possible that 
CSQ-DsRed tetramers led to even more complex polymers as a result of finite levels of 
CSQ2 polymerization that might occur even in the perinuclear region, although native 
CSQ2 does not typically accumulate (polymerize) in this compartment.   
Anti-DsRed fluorescence and CSQ-DsRed immunofluorescence were mutually 
exclusive because DsRed tetramerization simultaneously produces a bright red 
fluorescence [77] while effectively turning off antibody detection.  This generated 
separate assays for polymeric versus monomeric protein molecules that exhibited 
distinct patterns of intracellular trafficking.  Time-dependent features of the 
overexpression of CSQ-DsRed were particularly revealing.  CSQ-DsRed was initially 
detectable only by immunoreactivity, where it had a juxtanuclear localization.  At longer 
times, immunoreactive perinuclear CSQ-DsRed was replaced with the bright red 
fluorescence expected for DsRed tetramers in the same compartment.  However, 
whereas immunoreactive (monomeric) CSQ2 trafficked out of the perinuclear region, 
albeit slowly (Figs. 17,18), the red fluorescent tetramer was too large to traffic to 
junctional SR puncta to any significant extent [71, 85-86].  
By the end of a 48 h incubation period, the entire immunoreactive pool of CSQ2 
was concentrated at the cell periphery (Fig. 16F).  If immunoreactive CSQ-DsRed 
represents monomeric CSQ-DsRed, then the shift of this pool of protein from the 
perinuclear region to the cell periphery suggests that the input of additional 
immunoreactive CSQ-DsRed protein molecules was no longer occurring.  This may be 
directly due to the scavenging of all newly synthesized CSQ-DsRed within the 
fluorescent polymer within the perinuclear region once formed.  Thus, without further 
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input of newly-synthesized CSQ-DsRed, the "pulse" of monomeric CSQ-DsRed that 
escaped juxtanuclear polymerization could be visualized as it moved through the full 
extent of the Z-line localized ER/SR pathway.  The fate of this CSQ-DsRed that 
concentrated in the cell periphery after 48 h was not investigated in this study, but 
represents an interesting question for future studies.  
Protein markers of the ER translocon complex, TRAPα and TRAM, also had a 
juxtanuclear localization in the cardiomyocyte, suggesting that this is a major site of 
rough ER and CSQ2 biosynthesis.  Rough ER was previously visualized by electron 
microscopy in a continuum with the nuclear membrane, as one of a few 
morphologically-defined sites within adult rabbit cardiomyocytes [87].  Translation 
around myonuclei in cardiomyocytes for specific cardiac proteins has not been reported 
to our knowledge, but has been discussed as one of at least two such sites in skeletal 
muscle myocytes [88]. 
CSQ-DsRed fluorescence could be observed connecting the perinuclear region 
directly to adjacent junctional SR (RyR2-positive) puncta in optical sections that 
bisected the myonuclear midline (Figs. 12E, 14B2, asterisk).  A pathway for SR 
membrane protein trafficking along Z-lines has not previously been reported in 
cardiomyocytes, but may be similar to the exporting ER network described by Kaisto 
and Metsikkö in rat skeletal muscle myofibers [89].  We also observed apparent 
longitudinal trafficking of CSQ-DsRed, particularly when CSQ-DsRed-containing 
cisternae were viewed near the outer edges of the cell (Fig.16E,G,H).  A mechanism of 
longitudinal trafficking of CSQ2 is also not known, but our data for sec23, a microtubule-
based trafficking protein of COPII vesicles [84], suggests that junctional SR to 
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longitudinal SR might represent the normal direction of protein trafficking in the cardiac 
secretory pathway.  Free SR is enriched in proteins that contain the C-terminal KDEL 
retrieval sequence [90-92].  Because KDEL proteins are thought to be enriched in both 
ER and ERGIC [23, 93], their presence is consistent with free SR being a subcellular 
compartment distal to junctional SR.  The view of junctional SR as equivalent to ER, 
and longitudinal (or free) SR as being equivalent to the intermediate (ERGIC) 
compartment is consistent with studies from the Metsikkö laboratory in skeletal muscle 
myofibers [89, 94].  Similar to the limited accumulation of CSQ-DsRed in longitudinal SR 
(Fig. 16H), native CSQ2 that escapes retention by polymerization should also traverse 
this part of the cardiac secretory pathway, as do the other muscle-specific luminal 
ER/SR Ca2+-binding proteins sarcalumenin and histidine-rich Ca2+-binding protein [17].     
In a new model of CSQ2 biosynthesis and trafficking in cardiomyocytes (Fig. 19), we 
propose that CSQ2 is synthesized at sites within the nuclear envelope, and then traffics 
directly to junctional SR in the direction of the cell surface.  In the case of CSQ-DsRed, 
polymers (tetramers) are retained in rough ER and traffic slowly towards distal junctional 
SR only as tetramers dissociate to monomers. We infer from these data that CSQ2 
normally polymerizes only within junctional SR puncta, a process that prevents or slows 
its anterograde trafficking, and presumably its secretion.  We conclude therefore, that, 
as in the case of mammalian nonmuscle cells, CSQ2 polymerizes in junctional SR 
because it is the first intracellular compartment that satisfies the biophysical criteria for 
polymerization.   
The model presented here may help to explain previously reported CSQ2 protein 
structures in normal and hypertrophied hearts from small dogs [35].  In beagle heart 
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Figure 19.  Model of 
native CSQ2 trafficking 
from rough ER to 
junctional SR in 
cardiomyocytes.  (A) 
Native CSQ2 exists as 
monomers or linear 
polymers in dynamic 
equilibrium inside the 
secretory pathway of 
cardiomyocytes.  While 
monomeric CSQ2 traffics 
anterogradely, polymeric 
CSQ2 cannot, leading to 
its accumulation in 
junctional SR puncta.  
CSQ-DsRed, in contrast to 
native CSQ2, polymerizes 
and accumulates in rough 
ER around nuclei.  CSQ-
DsRed monomers, like 
CSQ2 monomers, can 
traffic anterogradely where 
they can be specifically 
detected by antibodies 
against either half of the 
fusion protein pair.  Not 
shown in this scheme are 
forms of CSQ2 in 
junctional SR that might 
contain CSQ-DsRed linear 
homopolymers and 
heteropolymers (with 
native CSQ2).  (B) In 
cardiomyocytes, native 
CSQ2 is synthesized in 
perinuclear rough ER.  
Trafficking proceeds 
across a direct cellular transport pathway (large arrow) to perinuclear junctional SR, dependent 
on a dynamic polymer (P)-monomer (M) equilibrium.  A predominance of native CSQ2 
monomers in rough ER and along the rough ER-junctional SR trafficking pathway led to 
anterograde trafficking.  CSQ2 polymers form within junctional SR puncta due to its distinctive 
intraluminal ionic conditions, leading to its accumulation [71].  ER-exit sites along this same ER 
pathway (highlighted by sec23 immunostaining, cf. Fig. 15), may separate the basic cardiac ER 
(junctional SR) from an intermediate compartment (longitudinal SR) that traffics along myofibrils 
(smaller arrows). In the case of CSQ-DsRed overexpression in cardiomyocytes, tetrameric 
CSQ-DsRed accumulates in rough ER.  Protein monomers of CSQ-DsRed predominantly traffic 
anterogradely to accumulate in peripheral junctional SR puncta.  Puncta in close proximity to 
cardiomyocyte nuclei may contain the inositol trisphosphate (IP3) receptor in addition to, or 
instead of the more prominent ryanodine receptor contained in more peripheral junctional SR 
puncta [95]. 
Figure 19
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tissue, CSQ2 molecules can be divided into two types based upon their glycan 
structures.  Most CSQ2 glycans show extensive mannose trimming (Man3-5), indicative 
of junctional SR localization [31, 34], but a minor portion of CSQ2 contains glycans 
indicative of rough ER localization (Man8,9) [23, 31].  This rough ER portion of CSQ2 
doubles in rapid-pacing induced heart failure, as does its state of phosphorylation [35].  
Moreover, ER forms of CSQ2 (Man9,8) in heart are fully phosphorylated, whereas 
junctional SR forms of CSQ2 (Man 3-6) are increasingly dephosphorylated [34].  
Phosphorylation by protein kinase CK2 may thus be responsible for its rough ER 
retention.  
CONCLUSIONS 
In summary, CSQ-DsRed fluorescence and immunofluorescence reveal several 
new aspects of CSQ biology by essentially slowing down its secretion, and by causing it 
to polymerize in a proximal compartment (rough ER).  Our new findings and 
accompanying model include: 1) the identification of the subcellular site of CSQ2 
biosynthesis (cardiac rough ER), 2) demonstration of a CSQ2 polymerization-dependent 
compartmentalization in cardiomyocytes, 3) the suggestion that CSQ-DsRed traffics 
directly from rough ER to junctional SR along a novel, albeit uncharacterized 
intracellular pathway, and 4) the characterization of rough ER and junctional SR as 
cardiac ER, and longitudinal SR as a compartment distal to ER exit sites possibly 
corresponding to ERGIC.  These data and model may aid in understanding the changes 
in CSQ2 and SR biology associated with new transgenic models and in diseases 
associated with inner membrane biology in adult cardiomyocytes.  
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CHAPTER 3 
IDENTIFICATION OF CARDIAC CALSEQUESTRIN KINASE AND THE EFFECTS OF 
C-TERMINAL PHOSPHORYLATION 
ABSTRACT 
 The luminal SR protein CSQ2 contains phosphate on roughly half of the 
serines found in its short cardiac-specific C-terminus.  The sequence around the 
phosphorylation sites in CSQ2 suggest that the in vivo CSQ2 kinase is protein kinase 
CK2, even though this enzyme is thought to be present only in the cytoplasm and 
nucleus.  To test whether CSQ2 kinase is protein kinase CK2, we combined 
experimental approaches directed at reducing the effects of CSQ2 phosphorylation in 
intact cells.  In vitro, tetrabromocinnamic acid (TBCA, 100 µM) inhibited both CSQ2 
kinase and CK2 activities by about 85% over the same range of concentrations.  In 
intact cultured primary adult rat cardiomyocytes and in COS cells, 24 h of TBCA (100 
µM) treatment produced a roughly 75% decrease in phosphorylation of CSQ2.  To 
further validate the identity of CSQ2 kinase as protein kinase CK2, we down-regulated 
both CK2α subunits in COS cells by transfection of appropriate siRNA, producing an 85-
90% decrease in CK2α and CK2α′ protein levels.  CK2-silenced cells exhibited a two-
fold reduction in CSQ2 kinase activity.  Endogenous CSQ2 overexpressed in CK2-
silenced COS cells was also reduced by a factor of two.  These pharmacologic and 
biochemical data suggest that CSQ2 in intact cells is phosphorylated by CK2, a 
cytosolic kinase (CK2) that could phosphorylate CSQ2 only during or before nascent 
protein translocation.  When CSQ2 phosphorylation site mutants were analyzed in COS 
cells, the characteristic rough ER form of the CSQ2 glycan (GlcNAc2Man9,8) 
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underwent phosphorylation-site dependent processing such that CSQ2-nonPP (Ser to 
Ala mutant) and CSQ2-mimPP (Ser to Glu mutant) produced apparent lower and 
greater levels of ER retention, respectively.  Taken together, our data support a 
hypothesis in which CK2 is able to phosphorylate CSQ2 co-translationally at 
biosynthetic sites in rough ER, a process that results in changes in its subsequent 
movements through the secretory pathway.  
INTRODUCTION 
Calsequestrin is a resident luminal protein of the SR [11, 19-20, 22, 33, 96] 
where an involvement in junctional Ca2+ release is assumed to be its primary function 
[13, 30].  The fast-twitch skeletal muscle CSQ1 and cardiac CSQ2 isoforms come from 
independent genes but share a relatively conserved sequence [33, 97].  Mammalian 
CSQ2 proteins have an 18-25 residue C-terminal extension that contains multiple 
serines in an otherwise highly acidic sequence, and is not present in CSQ1 [33, 98].  
These C-terminal serines are prolific in vitro substrates for an endogenous protein 
kinase, making CSQ2 by far the most heavily phosphorylated protein in heart cell 
homogenates, in the absence of exogenous kinase activators such as cyclic AMP [34].   
It is similarly phosphorylated in all mammalian cells following its overexpression [23, 31, 
34]. 
Both CSQ2 phosphorylation state and Asn(N)-linked glycan structure can be 
simultaneously determined by mass spectrometric analysis of purified CSQ2 protein 
[31, 35].  From these analyses, a great deal of information about the relationship 
between CSQ2 phosphorylation and its trafficking has been obtained.  For example, 
pathways of CSQ2 trafficking are revealed in the CSQ2 glycan structures, and it 
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appears clear that no CSQ2 in heart or nonmuscle cells ever leaves ER compartments.  
The CSQ2 glycan is comprised of only high-mannose structures GlcNA2ManN, where N 
= 3-9 depending upon the extent of mannose trimming [31, 34-35].  Recently, we have 
described novel ER-to-SR intracellular trafficking pathways in the adult cardiomyocyte, 
concluding that junctional SR represents bona fide ER. CSQ2 traffics directly from 
juxtanuclear rough ER to junctional SR where it is retained by its polymerization [99].  
Mannose trimming accompanies its anterograde trafficking in nonmuscle cells, whereas 
it is a hallmark of its rough ER to junctional SR trafficking in cardiac myocytes [23, 31, 
34]. We have also hypothesized that the longitudinal SR corresponds to the 
intermediate compartment (ERGIC), requiring proteins such as SERCA2a to enter ER 
exit sites that lie along the junctional SR pathway [99]. 
Mass spectrometry of intact purified CSQ2 also reveals significant insights into its 
phosphorylation.  When analyzed from heart tissue, newly synthesized molecules 
(having unprocessed glycans (Man9,8)) are found to exist only in the completely 
phosphorylated state [34].  Conversely, as CSQ2 undergoes mannose trimming in its 
trafficking to junctional SR, the number of unphosphorylated molecules dramatically 
increases, such that the most highly trimmed glycans contain no phosphate [34].  When 
analyzed in cultured nonmuscle cells, it is also evident that anterograde trafficking is 
also accompanied by CSQ2 dephosphorylation [23, 31, 34].     
Despite considerable knowledge about the CSQ2 phosphorylation reaction in 
nonmuscle cells and cardiac myocytes, the identity of the CSQ2 kinase has not yet 
been established.  There are no known luminal serine/threonine kinases identified in the 
literature, to our knowledge, that could serve as a candidate CSQ2 kinase in vivo.  The 
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putative identity of CSQ2 kinase derives from the fact that its C-terminal 
phosphorylation sites (Table 2) matches closely a consensus sequence (S/T-X-X-D/E) 
for the cytosolic serine/threonine protein kinase CK2 (formerly casein kinase 2) [37-38].  
CSQ2 is also a very efficient in vitro substrate for CK2 [34, 36].   
A paradox, however, results if one assumes that CK2 is the CSQ2 kinase, as 
CK2 has no signal sequence for gaining access to the ER lumen [100], whereas CSQ2 
is thought to be wholly contained within the SR lumen throughout its lifetime [12, 33].  
One hypothetical mechanism for reconciling the lack of co-localization with a co-
translational phosphorylation event would be that CSQ2 phosphorylation occurs prior to 
nascent polypeptide translocation across the rough ER membrane [64]. 
Mammalian protein kinase CK2, in the holoenzyme form, is composed of two 
separate catalytic subunits and two identical regulatory subunits [101].  The catalytic 
subunits, CK2α and CK2α′, share approximately 90% homology and are the product of 
different genes [44, 102-103].  Both catalytic subunits are capable of phosphorylating 
substrates independent of holoenzyme formation, and have been localized to different 
areas of the cell [101, 104-105].  CK2 has been shown to promote cell proliferation 
[106], and has recently become a chemotherapeutic target in order to promote tumor 
regression [107] leading to the advent of a series of new and highly specific inhibitors 
[61].   
 In this study, we have combined cellular and molecular approaches to investigate 
the actions of protein kinase CK2 on the cardiac-specific C-terminus of CSQ2.  
Reduced CSQ2 phosphorylation produced by reversible CK2-specific inhibitors, loss of 
CK2 protein by siRNA, and loss of phosphorylation by sequence mutations all support a 
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hypothesis in which phosphorylation of CSQ2 by the cytosolic protein kinase CK2 
occurs co-translocationally in rough ER to affect subsequent anterograde trafficking. 
MATERIALS AND METHODS 
Antibodies and commercial proteins 
Monoclonal antibody specific to CSQ2 was the generous gift of Dr. Larry Jones, 
Indiana University School of Medicine.  Mouse monoclonal antibody raised to human 
protein kinase CK2α catalytic subunit (CSNK2A1) and rabbit polyclonal antibody raised 
to human protein kinase CK2α′ catalytic subunit (CSNK2A2) were purchased from 
Abcam (ab70774 and ab10474).  Human CSNK2A1 (His-tagged CK2α) and CSNK2A2 
(GST-tagged CK2α′) recombinant proteins were purchased from Invitrogen (PV3248 
and PV3624). 
Cell culture  
COS-7 African green monkey kidney (COS) and human embryonic kidney 293 
cells (HEK-293), purchased from American Type Culture Collection, were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 25 mM HEPES, pH 7.4, 10% 
fetal bovine serum, 100 units/ml penicillin G, 0.1 mg/ml streptomycin and 0.25 μg/ml 
amphotericin B, at 37 °C with 5% CO2. 
Cardiomyocyte preparation 
Rat ventricular cells were enzymatically dissociated using a Langendorff 
perfusion apparatus, as previously described [99].  Heart cells were cultured on laminin-
coated dishes in modified Medium 199 containing 2% bovine serum.  Protein 
concentrations were determined according to Lowry et al. [108]. 
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CSQ2 plasmid and adenoviral constructs 
CSQ2 constructs and viral inserts were generated from wild type canine cardiac 
CSQ2 cDNA [33]. Creation and purification of adenoviruses for wild-type CSQ2 
(Ad.CSQ) and the non-phosphorylatable mutant Ad.nonPP (Ser 378,382,386 Ala) were 
previously described [31].  The phosphorylation mimic CSQ2 mutant Ad.mimPP was 
produced in an identical manner to that of Ad.nonPP except glutamates were used to 
replace the C-terminal serines (Ser 378,382,386 Glu).  Briefly, the mutating reverse 
primer (67-mer) contained 3 single base changes necessary for the Ser to Glu 
conversion.  PCR products were cloned into pBluescript (Stratagene), sequenced by the 
dideoxy method [109], and then subcloned into the pShuttle plasmid for virus 
construction (AdEasy System, American Type Culture Collection).  
Adenovirus-mediated overexpression 
Cells were treated with recombinant adenoviruses at a multiplicity of infection 
(MOI, pfu/cell) of 50 or 100 for COS and heart cells [31].  Purified viruses were added to 
cultured cells at the time of plating and left on throughout the overexpression period.     
Purification of overexpressed CSQ2 
Purification of CSQ2 from COS and cardiomyocyte cultures was carried out two 
days post-infection, as previously described [31] but with minor modifications.  Cell 
pellets were resuspended at roughly 1 mg/ml in extraction buffer containing 10 mM Tris, 
pH 8.0, 250 mM NaCl, 1% Triton X-100 and 1 mM EGTA.  Extracts were centrifuged at 
25,000 x g for 30 min, bound to 40 µl DEAE-Sephacel (Amersham Biosciences), 
washed, then eluted with 100 µl extraction buffer containing 500 mM NaCl.  SDS-PAGE 
analysis was carried out according to Laemmli [74]. 
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Preparation of native CSQ2 kinase sources 
Freshly isolated adult rat cardiomyocytes and cultured COS cells were pelleted 
and washed in PBS.  The pellets were resuspended in low ionic strength media 
containing 5 mM MOPS, pH 8.0, 1 mM EGTA and protease inhibition cocktail (Sigma 
P8340).  Suspensions were incubated on ice for 10 min and then passed through a 
255/8 ga. needle and glass/teflon homogenizer 10 times each.  NaCl was added to the 
resulting lysates (homogenates) to a concentration of 100 mM.  Detergent mixtures 
were created by adding Triton X-100 to the homogenates to a final concentration of 1%.  
Identical volumes (0.5 ml) of homogenates, detergent-free and detergent extraction 
mixtures were subjected to high speed centrifugation (30,000 x gmax for 15 min) in order 
to obtain homogenates and extracts.   
In vitro phosphorylation of purified CSQ2 
The standard CSQ2 phosphorylation reaction mixture for “back phosphorylation” 
consisted of 20 mM MOPS, pH 8.0, 150 mM NaCl, 0.5 mM EGTA, 10 mM MgCl2, and 
contained 20 µM [γ -32P]ATP (3000 cpm/pmol), 2 μg purified CSQ2 substrate, and a 
source of CSQ2 kinase, brought to a total volume of 50 µl with distilled water.  As a 
CSQ2 kinase source, either 2 μg of COS cell or cardiomyocyte homogenate or 
detergent extract was used, as indicated; or 0.1-0.4 µg purified human CK2α or CK2α' 
kinase was added as indicated.  Quantification of phosphate incorporation was 
determined by SDS-PAGE, autoradiography, and scintillation counting of radioactive 
bands excised from dried gels.  Measurements of “front phosphorylation”, or 
endogenous phosphorylation, included a pretreatment with or without 0.01 U acid 
phosphatase (P0157, Sigma) for 60 min in 10 µl of 30 mM MES buffer, pH 5.8, 0.1 mM 
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EGTA, as previously described [36], then dilution into phosphorylation buffer to a final 
volume of 50 µl.  For comparison with CK2α' commercial protein kinase activities, 2 µg 
of CSQ2 was used as substrate and equal units of kinase were compared: CK2α was 
0.5 U/µg, CK2α' was 0.25 U/µg (1 U = nmol Pi /mol RRRDDDSDDD peptide/min). 
Inhibition of CSQ2 kinase using specific inhibitors of protein kinase CK2 
 The CK2 specific inhibitors tetrabromocinnamic acid (TBCA, Calbiochem), 2-
dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole (DMAT, Calbiochem) and 4,5,6,7-
tetrabromobenzotriazole (TBB, Sigma) were dissolved in DMSO then diluted into 
phosphorylation reactions to varying micromolar concentrations to establish which was 
the most potent and gave the most consistent results.  To inhibit CSQ2 phosphorylation 
in intact cells, COS or heart cells were plated in 6-well dishes with Ad.CSQ for 24 h.  
TBCA (100 µM) or DMSO was then added for a total incubation time of 48 h, then cells 
were harvested for analysis. 
Mass spectrometry 
For mass spectrometry of CSQ-WT, CSQ-nonPP, and CSQ-mimPP, 
recombinant proteins were produced in HEK cells following the addition of respective 
viruses.  CSQ2 was purified and prepared for electrospray ionization mass spectrometry 
as previously described [23]. 
 RNAi 
HEK and COS cells were grown in 100 mm culture dishes for 24 hrs with or 
without Ad.CSQ or Ad.nPP, then transfected using DharmaFECT 1 transfection 
Reagent (Thermo Scientific T-2001-01), for 48 h with 100 nM Dicer-Substrate RNAi 
(DsiRNA, IDT), designed to silence either CSNK2A1 (IDT #HSC.RNAI.N177559.10.3), 
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CSNK2A2 (IDT #HSC.RNAI.N001896.10.2), or a combination of both.  Negative 
controls included no siRNA or DS NC1 universal DsiRNA negative control (IDT).  
Detergent extracts were created for use with standard back and front phosphorylation 
assays described above, after normalization by protein assay. 
mRNA analysis 
RNA extraction from COS cells overexpressing Ad.CSQ was performed using 
RNeasy Fibrous Tissue Mini Kit (Qiagen) according to manufacturer’s protocol.  RNA 
concentrations were determined by spectrophotometer at 260 nm.  One microgram of 
DNase-treated total RNA was reverse transcribed using a high-capacity cDNA reverse 
transcription kit (Applied Biosystems).  Quantitative real-time PCR (qPCR) with fast 
SYBR green (Applied Biosystems Step One with v2.0 software) was performed using 
CSQ2 primers designed to span one intron.  Relative quantitation was then used to 
evaluate mRNA levels compared to GAPDH internal control.  Canine CSQ2 forward 
primer: 5′- CCA AGC TTG CCA AGA AGC TGG GT -3′, reverse primer: 5′- ACG TCA 
GCT GCA AAC TCG CCA -3′. 
RESULTS 
Optimization of CSQ2 phosphorylation assays 
Native and overexpressed canine CSQ2 is phosphorylated in heart or nonmuscle 
cells on the same sites, and the reactions are assumed to occur by a similar CSQ2 
kinase associated in some way with the ER [31, 34].  We analyzed CSQ2 kinase activity 
from both primary rat cardiomyocytes and COS cells.  Both cell types were 
homogenized in the presence of Triton X-100 detergent to make CSQ2 kinase available 
to phosphorylate purified canine CSQ2 in vitro.  Determinations of reaction linearity as a 
50 
 
 
 
Figure 20.  Effects of cellular protein on CSQ2 kinase activity.  (A) increasing 
concentrations, 1, 2, 5, 10, 20, 30 or 50 µg of rat heart cell detergent extract or COS cell 
homogenate was used to phosphorylate 2 µg of purified native canine CSQ2 
(arrowheads).  Reaction mixtures were analyzed by SDS-PAGE (MW markers, 66 and 43 
kDa) and [32P]autoradiography.    (B) radioactive incorporation was determined, and 
kinase activity is shown on the y-axis.  (C,D) CSQ2 kinase activity was measured in 2, 5 
or 20 µg of homogenate, from a mild-detergent extraction of 2, 5 or 20 µg of homogenate, 
or from a detergent-free extraction of 2, 5 or 20 µg of homogenate derived from 
cardiomyocytes (C) or COS cells (D).  Inset, immunoblot of CK2α or CK2α' subunits from 
50 µg of COS cell homogenate (H), detergent extract (DE), or detergent-free extract 
(DFE).
function of protein (kinase source) were carried out with varying amounts of 
homogenate protein.  In contrast to an expected linear relationship between protein and 
kinase activity, increasing protein concentration actually exhibited an inverse 
relationship with CSQ2 phosphorylation (Fig. 20A,B); that is, increasing homogenate 
protein produced decreasing levels of [32P]-phosphate incorporation.  To remedy this 
extreme nonlinearity, we tested whether linearity could be better achieved using either a 
mild detergent extract or non-detergent extraction to separate the CSQ2 kinase from 
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possible interfering phosphatases or ATPases that might account for this effect.  We 
found that linearity was partially restored with extractions carried out in detergent, and 
more fully restored if detergents were removed (Fig. 20C,D).  Whether restoration of 
linearity was due to removal of CSQ2 phosphatase or cellular ATPases was not further 
investigated.  Based upon these determinations, CSQ2 kinase activities were generally 
measured using 2 µg of mild detergent extract.  Although the efficiency of CSQ2 kinase 
extraction could not be determined in these experiments because of the non-linearity, 
protein kinase CK2 recovery was only about 50% in detergent-free extracts based upon 
immunoblot analyses (Fig. 20D, inset).   
Pharmacological inhibition of CSQ2 phosphorylation in vitro 
Because of our previous in vitro evidence implicating CK2 as CSQ2 kinase [36], 
we tested the effects of new commercially available competitive inhibitors of CK2 [63] 
on CSQ2 kinase activity in cell extracts.  To allow us to compare effects of CK2-specific 
inhibitors, we first normalized endogenous CSQ2 kinase activities in myocytes, COS 
cells, and commercial CK2 by comparing their relative ability to phosphorylate 2 µg pure 
CSQ2.   Based upon these determinations, one would calculate that about 0.07% of 
cardiomyocyte protein and 1.7% of COS cell protein is CK2, if CK2 and CSQ2 kinase 
are the same protein and purified CK2α' maintains its native activity.  A value based 
upon immunoblotting of pure CK2 and COS cell extracts was closer to 1% of total 
protein, and consistent with a 25-fold lower level in cardiomyocytes (data not shown). 
Equal CSQ2 kinase activities from all three sources were then used to test 
inhibitors in vitro, using 2, 5, 10, 20, 50 or 100 µM concentrations of CK2-specific 
inhibitors TBB [110], DMAT [111] and TBCA [60] (Fig. 21A-C).  All three inhibitors were 
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Figure 21.  Effects of CK2 inhibition on CSQ2 kinase activity.  Measurements of 
CSQ2 kinase activities were carried out as described in Experimental Procedures using 
equivalent amounts of activity from cardiomyocytes (closed circles), COS cells (closed 
squares), or pure CK2α' (open circles).  Reactions included 0, 2, 5, 10, 20, 50 and 100 
µM concentrations of the CK2 inhibitors TBB (A), DMAT (B) or TBCA (C) (structures 
shown in respective insets).  Activities are shown (y-axis) as percent of control 
(untreated). 
capable of inhibiting endogenous CSQ2 kinase activity in both cardiomyocyte and COS 
cell extracts, and at concentrations similar to those required to inhibit commercial CK2 
phosphorylation of CSQ2.  The most potent of the three inhibitors was TBCA, which 
inhibited both endogenous CSQ2 kinase as well as commercial CK2 phosphorylation of 
CSQ2 at an IC50 of about 10 µM.  TBCA produced a near identical inhibition curve for all 
three kinase source reactions (Fig. 21C).  TBB and DMAT were also capable of 
inhibiting CSQ2 kinase and commercial CK2, but at higher micromolar concentrations 
(IC50 approximately 50 and 60 µM, respectively).  TBCA was chosen for subsequent 
experiments in cultured cells because it is reportedly the most specific and potent 
inhibitor of the three [60], and because we found TBCA to be the most soluble in culture 
media (data not shown). 
Pharmacological inhibition of CSQ2 phosphorylation in cultured cells   
 Our ability to inhibit cardiomyocyte and COS cell CSQ2 kinase in vitro, led us to 
determine whether TBCA would inhibit phosphorylation of CSQ2 during its 
overexpression in COS cells.  For both cell types, CSQ2 was overexpressed using an 
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Figure 22.  Reduction in endogenous CSQ2
phosphorylation in cells treated with TBCA.
COS cells or cardiomyocytes (Heart) were treated
with Ad.CSQ for 24 h in culture, then DMSO (C) or
100 µM TBCA was added for 24 h.  Cells were
extracted in mild-detergent, and levels of phosphate
on the overexpressed CSQ2 (Endog PP) were
determined for equal volumes of C or TBCA-treated
cell extracts using the front phosphorylation assay.
Endogenous phosphate on CSQ2 corresponds to
the difference in radioactivity between 32P-
incorporation after and before acid phosphatase
(PPase) treatment.  A sample autoradiogram is
shown for a measurement on partially purified CSQ2
protein from COS cells (upper panel).  Results are
also shown for multiple analyses of endogenous
CSQ2-phosphate content following its
overexpression in either COS cells or
cardiomyocytes for C or TBCA-treated cells (lower
panel, means  S.E.M., n=3).   
adenovirus to achieve high levels of 
biosynthesis in case CSQ2 
phosphorylation was tied to its rate of 
translation.  We previously showed 
using 32Pi-labeling in rat 
cardiomyocytes that endogenous 
CSQ2 phosphorylation is very low 
compared to similar amounts of 
virally overexpressed CSQ2 [34].  In 
experiments here, cardiomyocytes 
and COS cells were treated with 
Ad.CSQ for 24 h before an additional 
treatment with either 100 µM TBCA 
or vehicle (DMSO).  Levels of 
endogenous phosphate on CSQ2 
were determined from the difference 
between CSQ2 phosphorylation with 
and without phosphatase 
pretreatment.  We found that TBCA 
produced a potent inhibition of phosphate incorporation into CSQ2 in cultured 
cardiomyocytes and COS cells of 82 and 66%, respectively, compared to vehicle 
controls (Fig. 22).  The reduced effect of TBCA on CSQ2 phosphorylation in COS cells 
might just reflect the high levels of kinase in COS cells (Fig. 20B).  
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Figure 23.  Knockdown of CK2α and CK2α' using siRNA.  COS cells were 
transfected for 48 h with siRNA against either CK2α or CK2α', then extracted in mild 
detergent.  (A) untreated cells (“C”) or siRNA-treated cell samples (50 µg) were analyzed 
by immunoblotting using specific antibodies to detect CK2α  (~40 kDa) or CK2α' (~35 
kDa); compare to 45 kDa MW standard.  (B) shows the average levels of CK2α and 
CK2α' knockdown (si) as a percent of untreated (“C”) cells.  (C) shows the effects of 
CK2α plus CK2α' knockdown on CSQ2 kinase activity levels measured in detergent 
extracts of treated (si) and untreated (“C") COS cells.  Plots show means  S.E.M., n=3. 
siRNA knockdown of CK2 catalytic subunits 
To corroborate the pharmacologic data that supported identification of CSQ2 
kinase as CK2, RNAi experiments were performed.  Three separate siRNA mixtures 
that were tested were successful in silencing CK2α and CK2α' catalytic subunits at 100 
nM in either HEK or COS cells, as determined by immunoblotting of cell homogenates 
(Fig. 23A).  CK2α and CK2α' siRNA with the greatest knockdown efficiencies were used 
for subsequent experiments in cultured COS cells. 
To determine the effect of CK2 knockdown on CSQ2 kinase activity, we 
transfected COS cells with siRNA directed at both isoforms of the catalytic subunit.  
Protein levels for both CK2 isoforms, determined by immunoblotting, were reduced by 
approximately 95% over controls (Fig. 23B).  Extracts prepared from these siRNA-cells 
exhibited an approximate 2-fold reduction in CSQ2 kinase activity (Fig. 23C).  This 
decrease in CSQ2 kinase activity is notable given the high levels of CK2 present in 
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Figure 24.  Reduction in endogenous CSQ2 phosphorylation in cells treated with 
CK2 siRNA.  COS cells were treated with Ad.CSQ for 24 h in culture, then transfected with 
siRNA against CK2α plus CK2α' for an additional 48 h.  (A) Cells were extracted in mild-
detergent, and levels of phosphate on partially purified CSQ2 (Endog PP) were 
determined.  Individual samples of CSQ2 were normalized by immunoblotting.  A sample 
autoradiogram is shown for purified CSQ2 samples for untreated control (“C”) and siRNA-
treated COS cells (upper panel).  Results are also shown (lower panel) from multiple 
analyses of endogenous CSQ2-phosphate content for C and siRNA-treated cells 
(meansS.E.M., n=4).  (B) similar Ad.CSQ-treated COS cells (C or siRNA-treated) were 
metabolically labeled with 35S[Met] for 2 h, and identical sample volumes were analyzed by 
SDS-PAGE.  The gel was stained with Stains-All to highlight CSQ2 as a dark-blue protein 
band on a pink background (arrowhead), then destained and re-stained with Coomassie 
blue, then dried and placed against film for autoradiography.  MW standards (left) are in 
kDa.  The 66 kDa standard is albumin, which also contaminates the sample cultures from 
the serum in the medium.  (C) effects of CK2 siRNA on CSQ2 mRNA levels determined by 
triplicate qPCR measurements (means  S.E.M., n=3).    
COS cells (Fig. 20B) and the potential that siRNA does not silence all cellular pools of 
CK2 equally, such as those with differing rates of protein turnover.  CSQ2 kinase 
activities from cells following silencing of individual CK2 isoforms could not resolve 
subunit-specific effects because of apparent compensatory changes in each CK2α 
isoform that occurred after 48 h of knockdown. 
 To determine whether CK2 knockdown would decrease the level of endogenous 
CSQ2 phosphorylation in intact cells, COS cells overexpressing canine CSQ2 were 
treated with CK2 siRNA.  In accordance with the roughly 2-fold decrease in CSQ2 
kinase activity caused by CK2 siRNA transfection (Fig. 23C), we measured a 2-fold 
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Table 2.  CSQ2 phosphoform variants. 
decrease in the levels of phosphate in CSQ2 in COS cells (Fig. 24A).  This loss of 
endogenous phosphate occurred despite a 24 h period of overexpression prior to siRNA 
treatment.  Moreover, even with CK2 protein diminishing over the course of the 
treatment period, an ongoing phosphorylation of CSQ2 would have occurred due to the 
exquisite affinity of CSQ2 for CK2 [36].    
 A complicating effect of CK2 siRNA in COS cells was an increase in protein on 
SDS-gels, including significant changes in overexpressed CSQ2 (Fig. 24B).  The 
change could be seen by protein stain, as well as following a 2 h [35S]methionine 
labeling of cells.  Analysis by qPCR of CSQ2 mRNA in treated and untreated cells 
showed a roughly 2-fold increase (Fig. 24C).  Whether transcriptional or translational 
changes accounted for observed changes in cellular protein was not further 
investigated.  Measurements of CSQ2 phosphorylation were therefore carried out by 
first purifying CSQ2 from cellular extracts, normalizing CSQ2 levels using antibody 
binding (immunoblot) analyses, then using standard phosphate analysis assays.  
Effects of CSQ2 phosphorylation site mutation on protein trafficking in 
nonmuscle cells   
To determine whether CSQ2 phosphorylation could affect its trafficking, we 
examined purified wild-type CSQ2 (CSQ-WT) and phosphorylation-site mutants (Table 
2) by electrospray mass spectrometry to determine the details of their polymorphic 
structure [31].  CSQ-WT was composed primarily of molecules having glycans with 
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Figure 25.  Effects of CSQ2 phosphorylation site sequence on glycan structure in 
nonmuscle cells.  Cultured nonmuscle cells were treated with recombinant 
adenoviruses encoding either the wild-type CSQ2 sequence (WT), the 
Ser(378,382,386)Ala triple point mutant (nonPP), or the Ser(378,382,386)Glu mutant 
(mimPP) for 48 h, then CSQ2 was purified and analyzed by mass spectrometry as 
described in Experimental Procedures.  Sample mass spectra are shown for each 
purified sequence of CSQ2 (A-C).  Numbers 5-9 refer to the number of mannoses in the 
glycan that correspond to the mass values shown along the bottom axis.  Minor levels of 
peaks that differ in mass by 20-40 Da, are likely to correspond to cation-bound 
molecules, and varied among spectra.  Mannose content for the three CSQ2 structures 
are shown as aligned, although there were minor differences in mass due to the 
sequence mutations.  Molecular weights (bottom) are those corresponding to the WT 
sequence.  (D) The percentages of total CSQ2 molecules that exhibited mannosidase 
trimming to below 8 mannoses (non-ER glycan) are shown from multiple experiments 
(means  S.E.M., n=3). 
structures of GlcNAc2Man9 and GlcNAc2Man8 (Man9,8) with only minor amounts or no 
Man7 (Fig. 25A).  In addition, these CSQ-WT molecules contained peaks of 
phosphorylated protein with a spacing of 81 Da (Fig. 25A, shaded) as previously 
described [23, 31].  Replacement of phosphorylatable serines with alanines (CSQ-
nonPP) led to loss of all CSQ2 phosphorylation along with the appearance of lower-
mass forms of the protein that correspond to increased levels of mannose trimming (Fig. 
25B).  We previously showed in COS cells that mannose trimming beyond Man9,8 
occurs for CSQ2 molecules that are not efficiently retained in ER [23].  
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To determine whether this effect on CSQ2 trafficking was purely due to the loss 
of phosphorylatable serines, we carried out the same analysis following replacement of 
serines with glutamates (CSQ-mimPP).  In contrast to CSQ-nonPP, CSQ-mimPP 
molecules gave structures similar to that of CSQ-WT (Fig. 25C).  Multiple spectra from 
independent CSQ-WT, CSQ-nonPP and CSQ-mimPP samples were analyzed in order 
to compare the percent of total CSQ2 leaving ER as represented by mannoses less 
than 8 and 9 (Fig. 25D).  Thus, the CSQ2 kinase appears to be acting at a co-
translational site within the cell, and a resultant increase in CSQ2 phosphorylation may 
alter its ability to exit that site of biosynthesis. 
DISCUSSION 
CSQ2 kinase as protein kinase CK2  
In mammalian heart tissue, CSQ2 exists as a highly phosphorylated protein [31, 
34, 36].  Endogenous phosphate is found only on a cluster of 2 or 3 serine residues 
(depending upon the species) that are found in the cardiac C-terminal extension.  This 
CSQ2 phosphorylation reaction is essentially the same in all mammalian cells examined 
to date, whether one examines native or overexpressed CSQ2 [23, 31].  In intact heart 
tissue, CSQ2 appears to be phosphorylated early in its biosynthesis in rough ER based 
upon the fact that newly synthesized molecules (Man 9,8,7) only exist in the fully 
phosphorylated state, whereas the most highly trimmed glycans (Man 2,3,4) are mostly 
devoid of phosphate [34].  A critical question that has remained unresolved in this 
process, however, is whether the CSQ2 kinase is protein kinase CK2.  We previously 
showed that CSQ2 phosphorylation sites adhere closely to the consensus sequence for 
protein kinase CK2, and CSQ2 is exquisitely sensitive to CK2 in vitro [12].  However, if 
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CK2 is the CSQ2 kinase, it raises the important question of how CSQ2, a luminal ER 
protein, can be phosphorylated by what is believed to be a cytosolic enzyme.  CK2 has 
no known mechanism for localizing to the ER/SR lumen where CSQ2 is thought to be 
wholly contained throughout its lifetime [17].  Only when the CSQ2 C-terminus is in the 
process of traversing the translocon pore complex could such an association 
theoretically occur [32].  Such a process suggests that CSQ2 phosphorylation is a co-
translational event, and CK2 could be associated with the translocon, similar to the 
association of the oligosaccharide transferase complex (OST) that brings about co-
translational N-linked glycosylation.  CK2 has previously been shown to play a role in 
assembly of the translocon pore complex and signal sequence through phosphorylation 
of sec63 [112].  Calnexin, another resident ER protein, is a transmembrane protein that 
undergoes interaction with the ribosome in response to phosphorylation of its 
cytosolically exposed CK2 site [56].  We have previously reported that a number of 
resident ER/SR proteins are substrates for CK2 in vitro [17], perhaps suggesting that 
the reaction mechanism described in this paper may play a wider role in ER/SR biology.  
To show that protein kinase CK2 is the physiological enzyme that modifies CSQ2 
in vivo, this series of studies altered the reaction in a mammalian nonmuscle cell model 
system.  Based upon our data from several experimental approaches, we conclude that 
CK2 is likely to be the native CSQ2 kinase that is present in all mammalian cells.  This 
necessitates a co-translational or co-translocational phosphorylation event occurring for 
CSQ2.  The differences we found in the glycan structures of CSQ2 phosphorylation site 
mutants support this conclusion, indicating that a proximal phosphorylation event affects 
subsequent CSQ2 trafficking, reflected in its mannose trimming, within the secretory 
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pathway.   
CSQ2 kinase activity and its inhibition 
Whether CK2 activity was competitively inhibited using TBCA, a highly specific 
inhibitor of CK2 [60], or biospecifically down-regulated using RNAi technology, CSQ2 
kinase activity was affected in parallel.  These data show that the CSQ2 kinase that 
exists in preparations derived from all mammalian cells [23] is likely the result of protein 
kinase CK2.  Reduced levels of CSQ2 kinase that remain in cell extracts following CK2 
inhibition or down-regulation, we believe, are unlikely to emanate from a second 
unknown CSQ2 kinase, although further studies may be warranted. 
The advent of highly specific inhibitors of CK2 has also been driven by the fact 
that these compounds exhibit anti-growth and anti-cancer activities [58-59], reflecting an 
important role of CK2 in cell growth.  The fact that CSQ2 is the major substrate for CK2 
in heart homogenates is consistent with a possible role of CSQ2 phosphorylation in 
cardiac hypertrophy.  We have previously shown that CSQ2 phosphorylation is doubled 
in canine tachycardia-induced heart failure [35].   
In contrast to the relatively immediate inhibition of all available CK2 catalytic 
subunits using TBCA, siRNA inhibition was expected to be more gradual requiring 
turnover of the existing kinase pool, as suggested by Zhu et al. [59].  Furthermore, we 
cannot be certain that turnover of all CK2 pools within the cell are the same, whereas 
ATP binding sites are likely to be identical.  Because both subunits are capable of 
efficiently phosphorylating CSQ2 in vitro (data not shown), simultaneous CK2α/α′ 
knockdown was needed to verify the identity of CK2 as CSQ2 kinase.  Analysis by 
immunoblot usually showed a putative compensatory increase in subunit partner in 
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single subunit down-regulation experiments that was not further investigated.  In spite of 
these differences in mechanisms, both CK2 inhibition techniques produced qualitative 
decreases in CSQ2 kinase activity, and each was able to lower phosphate incorporation 
in overexpressed CSQ2.  Minor quantitative differences in the degrees of CSQ2 kinase 
inhibition were likely to have reflected their very different mechanisms of CK2 inhibition. 
Experimental determinations of CSQ2 kinase and phosphorylation
 Measurements of in vitro CSQ2 phosphorylation were found to be surprisingly 
nonlinear; and in fact produced lower levels of CSQ2 phosphorylation using higher 
levels of protein in the phosphorylation assay.  In principle, the problems we uncovered 
should plague any and all determinations of kinase activity in crude preparations, such 
as those used in this study.  Our data suggest that endogenous ATPases represent 
potentially confounding activities, such that it is necessary to use minimal cellular 
protein extract along with mild extraction techniques to accurately determine in vitro 
phosphorylation rates.  Understanding these limitations, we were able to demonstrate 
the potential utility of these CK2 inhibitors for use as cellular probes. 
Studies aimed at determining effects of CK2 reduction on phosphate levels in 
CSQ2 were carried out in CSQ2-adenovirus treated cells.  As previously observed from 
32P-labeling reactions in cultured rat cardiomyocytes [34], the higher rate of CSQ2 
biosynthesis obtained through Ad.CSQ2 treatment was needed to observe 
phosphorylation, presumably because of its elevated rate of biosynthesis and co-
translational phosphorylation.  CK2 silencing itself, however, produced increases in 
cellular and CSQ2 protein synthesis that affected steady state protein levels after 48 h 
in culture, as well as [35S]Met incorporation over a 2 h period (Fig. 24B).  CSQ2 
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purification, however, permitted measurements of CSQ2 phosphorylation state by using 
our standard assay with equal amounts of CSQ2.  Thus, reductions of CK2 activity 
through either of two separate approaches in cultured cells reduced levels of cellular 
CSQ2 kinase activity, and reduced endogenous CSQ2 phosphate content.   
Protein kinase CK2 regulation of CSQ2 trafficking 
Based upon identification of CSQ2 kinase in intact cells as the cytosolic protein 
kinase CK2, our previous hypothesis that CSQ2 phosphorylation is a co-translational 
event [34] can be expanded.  In our new model (Fig. 26), we hypothesize that CSQ2 
phosphorylation occurs before the C-terminal tail has entered the lumen of the protein 
pore complex (sec61) or ER lumen [113].  One possible mechanism might be a 
translocation pause wherein the ribosome separates from the translocon permitting a 
transient co-localization of CK2 and CSQ2 [64, 113].  If such a process, so proximal in 
the secretory pathway, were to affect the subsequent trafficking of CSQ2 through the 
secretory pathway, mannose trimming alterations would not be unexpected.  
 
 
Figure 26.  Hypothetical mechanism of cardiac CSQ phosphorylation by CK2 in rough 
ER during translocation across the ER membrane.  A mechanism whereby an ER 
protein such as CSQ2 becomes exposed to cytoplasmic CK2 would require that the ER-
bound ribosome permits access to the nascent CSQ2 polypeptide after completion of 
translation but during its translocation through the translocon.  Other known translocon 
accessory proteins, such as TRAP and TRAM [99] are present in cardiomyocyte rough ER 
and could function in such translocational regulation [64]. 
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 Intracellular localization of CSQ2 can consistently be predicted from its N-linked 
glycan structure in a number of mammalian cell types including cardiomyocytes.  In this 
study, comparisons of glycan structures for CSQ-WT, CSQ-nonPP, and CSQ-mimPP 
showed that only the CSQ-nonPP form exhibits excessive mannose trimming, indicative 
of increased trafficking away from rough ER.  Glutamate, a commonly used 
phosphomimetic substitution, showed a marked reversal of this effect on glycan 
structure.  These results support the idea that CSQ2 phosphorylation is associated with 
its biosynthesis and affects retention of CSQ2 in ER. 
In heart failure, the detailed structure of CSQ2 is dramatically shifted.  A peak of 
newly synthesized CSQ2 (with Man9,8 glycans) accumulates instead of continuing 
through its normal trafficking cycle [35], indicating that this newly synthesized protein is 
being retained within rough ER structures.  Rough ER, as we have recently 
demonstrated, is localized to juxtanuclear cisternae in cardiomyocytes [99].  Together 
with findings reported here, we hypothesize that changes in CK2 activity and/or 
localization in heart failure increase CSQ2 phosphorylation with consequent ER 
retention, to favor a perinuclear Ca2+ microdomain shift facilitating increased 
transcription or translation in hypertrophy.  
CONCLUSIONS 
In conclusion, findings generated from multiple experimental approaches in this 
study support an emerging picture of CSQ2 phosphorylation as a co-translational 
process, which we now hypothesize is co-translocational as well.  Verification that CK2 
is the in vivo CSQ2 kinase implicates the involvement of the rough ER translocon in this 
biological reaction.  The dependence of CSQ2 glycan structure on its state of 
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phosphorylation has consistently revealed important features of this reaction, both here 
using CSQ2 phosphorylation site mutants as well as for CSQ2 in failing hearts.  These 
studies should guide future investigations by establishing a basic biochemical paradigm 
for CSQ2 phosphorylation in the mammalian cell. 
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CHAPTER 4 
SUMMARY 
 Cardiac CSQ is a multifaceted protein, capable of binding significant quantities of 
Ca2+ and altering RyR2 activity at junctional SR.  The site of CSQ2 synthesis, however, 
is not junctional SR.  This fact has been largely overlooked in the field of cardiac cell 
biology, coinciding with a tendency to picture protein distribution in the cardiomyocyte 
as a static system.  The reality is that CSQ2 is constantly being made and trafficked 
from its site of biosynthesis in perinuclear rough ER to junctional SR in a 
polymer/monomer, phosphorylation-dependent manner. 
 With the majority of cardiac biochemists focusing on junctional SR Ca2+ release, 
little thought has been given to the basic questions that one assumes would have been 
answered prior to the study of complex cell biology.  Accordingly, the location of rough 
ER in cardiomyocytes has never been elucidated.  There is often a comparison between 
skeletal muscle myocytes, for which cell biology is slightly more established, and 
cardiac myocytes.  This extrapolation may not be applicable in terms of protein 
synthesis however as traditional cell biology dictates that rough ER surrounds the 
nucleus and would therefore increase if more nuclei were present.  This is the case as 
skeletal muscle cells are polynucleated while cardiac muscle cells are binucleated in a 
symmetrical manner.  
 Through the use of multiple antibodies specific to classic rough ER markers, and 
with the CSQ-DsRed fusion protein, we were able to establish a juxtanuclear 
localization of rough ER in cardiomyocytes.  Using fluorescence confocal microscopy, 
the translocon complex proteins TRAP-α and TRAM, along with the ribosomal protein 
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S6, were all visualized and found to encapsulate both myonuclei.  Additionally, time 
course studies of the CSQ-DsRed tetramer, in conjunction with anti-DsRed 
immunostaining, highlighted a perinuclear rough ER site of biosynthesis for CSQ2 and 
presumably all other proteins in the secretory system. 
  Following CSQ-DsRed translation, the fusion protein built up in the ER 
surrounding the nuclei due to DsRed tetramerization, and then trafficked anterogradely 
to junctional SR.  Filling of more peripheral junctional SR puncta occurred with 
increasing incubation time.  With the exception of CSQ-DsRed concentration around the 
nuclei, DsRed fusion protein tetramerization-dependent trafficking is predicted to be 
very similar to CSQ2 polymerization-dependent trafficking likely caused by the Ca2+ 
properties of secretory pathway compartments.   
 Cardiac-specific C-terminal phosphorylation of CSQ2 serines was also shown to 
effect CSQ2 trafficking according to mass spectrometric analysis of the protein’s N-
linked glycan.  A Ser 378,382,386 Ala mutation (CSQ-nonPP) of these sites inhibited 
CSQ2 phosphorylation and led to an increased trafficking out of the ER as indicated by 
the increased mannose trimming of CSQ2 glycan.  This effect was reversed with the 
phosphomimetic mutant Ser 378,382,386 Glu (CSQ-mimPP) which had glycoforms with 
mannose trimming nearly identical to that of CSQ-WT. 
 Pharmacological and molecular inhibition were used to establish the identity of 
CSQ2 kinase as protein kinase CK2.  In vitro, inhibition of CSQ2 phosphorylation using 
cardiomyocyte and nonmuscle cell CSQ2 kinase sources was successfully carried out 
with three specific inhibitors of CK2:  TBB, DMAT and TBCA.  TBCA produced identical 
inhibition curves for both cellular kinase sources and commercial CK2α′ kinase, with 
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increasing concentrations of drug.  SiRNA knockdown of both CK2α and CK2α′ catalytic 
subunits in nonmuscle cells reduced CSQ2 kinase activity by nearly 2-fold according to 
similar in vitro CSQ2 phosphorylation assays. 
 Additionally, both ATP-binding site competitive inhibition and CK2 RNAi protein 
inhibition were used successfully in situ to suppress endogenous CSQ2 
phosphorylation.  TBCA used at 100 µM with CSQ-WT overexpressing cardiomyocytes 
and COS nonmuscle cells in culture led to an 82 and 66% decrease in CSQ2 phosphate 
incorporation, respectively, compared to control.  Similarly, simultaneous knockdown of 
both CK2α and CK2α′ catalytic subunits in COS cells overexpressing adenoviral CSQ-
WT, caused a near 2-fold decrease in CSQ2 phosphate incorporation, further 
supporting the identity of CSQ2 kinase as protein kinase CK2. 
 These studies present a global model for CSQ2 trafficking regulation in 
cardiomyocytes.  As CSQ2 is translated at perinuclear rough ER, its C-terminus is 
exposed to the cytosolic protein kinase CK2 allowing for CSQ2 phosphorylation prior to 
translocation into the ER lumen.  A combination of dephosphorylation and 
monomerization then promote anterograde trafficking through the secretory system.  
CSQ2 subsequently becomes retained in junctional SR compartments due to increasing 
Ca2+ concentrations, which leads to polymer formation.  Following a decrease in Ca2+ 
levels, CSQ2 monomerizes to once again traffic anterogradely through the secretory 
system.  
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APPENDIX 
LIST OF ABBREVIATIONS 
Ad.CSQ  wild-type cardiac calsequestrin adenovirus 
Ad.CSQ-DsRed adenoviral cardiac calsequestrin-DsRed 
Ad.CSQ-HA  adenoviral cardiac calsequestrin with hemagglutinin epitope tag 
Ad.mimPP  constitutively-phosphorylated cardiac calsequestrin adenovirus 
Ad.nonPP  nonphosphorylatable cardiac calsequestrin adenovirus 
CICR   calcium-induced calcium release 
COS   COS-7 African green monkey kidney cells 
CPVT   catecholaminergic polymorphic ventricular tachycardia 
CSNK2A1  protein kinase CK2α catalytic subunit 
CSNK2A2  protein kinase CK2α′ catalytic subunit 
CSQ   calsequestrin 
CSQ-DsRed  cardiac calsequestrin pDsRed2-N1 fusion protein 
CSQ-mimPP  constitutively-phosphorylated cardiac calsequestrin 
CSQ-nonPP  nonphosphorylatable cardiac calsequestrin 
CSQ-WT  wild-type cardiac calsequestrin 
CSQ1   skeletal calsequestrin 
CSQ2   cardiac calsequestrin 
CSQ-HA  cardiac calsequestrin with hemagglutinin epitope tag 
DAPI   4′-6-diamidino-2-phenylindole 
DMAT   2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole 
DMEM  Dulbecco’s Modified Eagle’s Medium 
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DRB   5,6-dichloro-1-(β-ɒ-ribofuranosyl)-benzimidazole 
DsiRNA  Dicer-Substrate siRNA 
ECL   electrochemiluminescence 
ER   endoplasmic reticulum 
ERGIC  ER-Golgi intermediate compartment 
ESMS   electrospray mass spectrometry 
GlcNAc  N-acetyl-D-glucosamine 
HEK   human embryonic kidney 293 cells  
HF   heart failure 
HRP   horseradish peroxidase 
IP3R   inositol trisphosphate receptor  
Jct   junctin 
Man   mannose 
MOI   multiplicity of infection 
NCX   Na+/Ca2+ exchanger 
OST   oligosacharyl transferase complex 
RNC   ribosome nascent chain complex 
RyR   ryanodine receptor 
RyR2   cardiac ryanodine receptor 
SERCA2a  cardiac sarco/endoplasmic reticulum Ca2+-ATPase 
SP/SPC  signal peptidase complex 
SR   sarcoplasmic reticulum 
SRP   signal recognition particle 
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SRP-R  signal recognition particle receptor 
T-tubules  transverse tubules 
TBCA   tetrabromocinnamic acid 
TBB   4,5,6,7-tetrabromobenzotriazole 
TRAM   translocating chain-associated membrane protein 
TRAP   translocon-associated protein complex 
Trd/Trd1  triadin-1 
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 Cardiac CSQ (CSQ2) is a multifaceted protein, capable of binding significant 
quantities of Ca2+ and altering ryanodine receptor activity at the junctional sarcoplasmic 
reticulum (SR).  Little is known about the trafficking of CSQ2 from its unknown site of 
biosynthesis, which appears to be of importance as its structure changes in a trafficking-
dependent manner in various types of heart failure.  Through the use of multiple 
antibodies specific to classic rough ER markers, and with the creation of CSQ-DsRed 
tetramer fusion protein, we were able to establish a juxtanuclear localization of rough 
ER in cardiomyocytes.  Using fluorescence confocal microscopy, the translocon 
complex proteins TRAP-α and TRAM, along with the ribosomal protein S6, were all 
visualized and found to encapsulate both myonuclei.  Additionally, time course studies 
of CSQ-DsRed, in conjunction with anti-DsRed immunostaining, highlighted a 
perinuclear rough ER site of biosynthesis for CSQ2.  The fusion protein exhibited a 
tetramerization-dependent trafficking predicted to be very similar to CSQ2 
polymerization-dependent trafficking with high and low secretory compartment Ca2+ 
concentrations leading to polymerization and monomerization, respectively.    
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 Cardiac-specific C-terminal phosphorylation of CSQ2 serines was shown to 
effect CSQ2 trafficking according to mass spectrometric analysis of the protein’s N-
linked glycan.  A Ser 378,382,386 Ala mutation (CSQ-nonPP) of these sites inhibited 
CSQ2 phosphorylation and led to an increased trafficking out of the ER as indicated by 
the increased mannose trimming of CSQ2 glycan.  This effect was reversed with the 
phosphomimetic mutant Ser 378,382,386 Glu (CSQ-mimPP) which had glycoforms with 
mannose trimming nearly identical to that of CSQ-WT. 
 Pharmacological and molecular inhibition were used to establish the identity of 
CSQ2 kinase as protein kinase CK2.  In vitro, inhibition of CSQ2 phosphorylation using 
cardiomyocyte and nonmuscle cell CSQ2 kinase sources was successfully carried out 
with three specific inhibitors of CK2:  TBB, DMAT and TBCA.  TBCA produced identical 
inhibition curves for both cellular kinase sources and commercial CK2α′ kinase, with 
increasing concentrations of drug.  SiRNA knockdown of both CK2α and CK2α′ catalytic 
subunits in nonmuscle cells reduced CSQ2 kinase activity by nearly 2-fold according to 
similar in vitro CSQ2 phosphorylation assays. 
 Additionally, both ATP-binding site competitive inhibition and CK2 RNAi protein 
inhibition were used successfully in situ to suppress endogenous CSQ2 
phosphorylation.  TBCA used at 100 µM with CSQ-WT overexpressing cardiomyocytes 
and COS nonmuscle cells in culture led to an 82 and 66% decrease in CSQ2 phosphate 
incorporation, respectively, compared to control.  Similarly, simultaneous knockdown of 
both CK2α and CK2α′ catalytic subunits in COS cells overexpressing adenoviral CSQ-
WT, caused a near 2-fold decrease in CSQ2 phosphate incorporation, further 
supporting the identity of CSQ2 kinase as protein kinase CK2. 
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 These studies present a global model for CSQ2 trafficking regulation in 
cardiomyocytes.  As CSQ2 is translated at perinuclear rough ER, its C-terminus is 
exposed to the cytosolic protein kinase CK2 allowing for CSQ2 phosphorylation prior to 
translocation into the ER lumen.  A combination of dephosphorylation and 
monomerization then promotes anterograde trafficking through the secretory system.  
CSQ2 subsequently becomes retained in junctional SR compartments due to increasing 
Ca2+ concentrations, which led to polymer formation.  Following a decrease in Ca2+ 
levels, CSQ2 monomerizes to once again traffic anterogradely through the secretory 
system.  
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